Antigen-binding molecule specifically binding to GPRC5d and CD3 and medical use thereof

By designing antigen-binding molecules that specifically bind GPRC5D and CD3, the shortcomings of existing multiple myeloma treatment methods are solved, and efficient targeted treatment of multiple myeloma cells is achieved, which reduces side effects and provides new targets. Immunotherapy options.

WO2023174238A9PCT designated stage expired Publication Date: 2024-12-05JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/081237
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-03-14
Filing Date
2023-03-14
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The existing multiple myeloma (MM) treatments have many disadvantages, including birth defects and neurotoxicity caused by immunomodulators, peripheral neurotoxicity, high risk and drug resistance problems of protease inhibitors, and failure to completely cure the disease. , leading to recurrence.

Method used

Develop an antigen-binding molecule that specifically binds GPRC5D and CD3, including an antigen-binding module that specifically binds GPRC5D and an antigen-binding module that specifically binds to CD3, using specific amino acid sequences and structure designs to form antibodies in Fab or scFv form to target Treat multiple myeloma cells.

Benefits of technology

The antigen-binding molecule is able to efficiently target multiple myeloma cells, reduce damage to normal cells, potentially improve therapeutic effects and reduce side effects, providing a new targeted immunotherapy option that may effectively cure or prolong patient survival.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2023081237-FTAPPB-I100001
    Figure PCTCN2023081237-FTAPPB-I100001
  • Figure PCTCN2023081237-FTAPPB-I100002
    Figure PCTCN2023081237-FTAPPB-I100002
  • Figure PCTCN2023081237-FTAPPB-I100003
    Figure PCTCN2023081237-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are an antigen-binding molecule specifically binding to GPRC5D and CD3, and the medical use thereof. The antigen-binding molecule can be used for treating tumor-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Antigen binding molecules specifically binding to GPRC5D and CD3 and their medical uses Technical Field

[0001] The present disclosure belongs to the field of biotechnology, and more specifically, relates to antigen-binding molecules and applications thereof. Background Art

[0002] The statements herein merely provide background information related to the present disclosure and do not necessarily constitute prior art.

[0003] Multiple myeloma (MM) is the second most common hematological malignancy with a 5-year survival rate of approximately 53.9%. As the global population ages, the incidence rate is expected to increase.

[0004] GPRC5D, a G protein-coupled orphan receptor (GPR5D), is a seven-transmembrane protein that is specifically overexpressed in multiple myeloma patients and correlates with poor prognosis, whereas it is barely expressed in most normal tissues. Furthermore, GPR5CD expression is significantly higher in both newly diagnosed and relapsed / refractory MM patients compared to healthy controls. Furthermore, GPRC5D expression remains unchanged in various aberrant cell types, including those with 1(q)gain and 13(q)del. This association between GPRC5D overexpression and cancer suggests that GPRC5D may serve as an excellent therapeutic target for cancer.

[0005] There are currently many therapeutic drugs for MM in clinical practice, including immunomodulators (IMIDs), protease inhibitors (PIs), and monoclonal antibodies. These drugs have indeed improved the clinical condition of MM patients, but these therapies all have their own disadvantages. For example, IMIDs can cause birth defects, neurotoxicity, and severe thrombosis, while PIs are accompanied by a high risk of peripheral neurotoxicity. Monoclonal antibodies against CD38 and SLAMF7 can cause severe infections and anemia due to the reduction of red and white blood cells, and can also cause drug resistance due to antigen loss. Currently, there is no treatment that can completely cure MM, and patients will eventually relapse. Therefore, the development of a new targeted immunotherapy is of relatively important clinical significance.

[0006] Summary of the Invention

[0007] The present disclosure provides an antigen binding molecule that specifically binds to GPRC5D and CD3, and an antibody that specifically binds to GPRC5D.

[0008] In one aspect, the present disclosure provides an antigen binding molecule that specifically binds to GPRC5D and CD3, comprising at least one antigen binding moiety that specifically binds to GPRC5D and at least one antigen binding moiety that specifically binds to CD3, the antigen binding moiety that specifically binds to GPRC5D comprises a heavy chain variable region GPRC5D-VH and a light chain variable region GPRC5D-VL, and the antigen binding moiety that specifically binds to CD3 comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL. In one aspect, the present disclosure provides an antigen binding molecule that specifically binds to GPRC5D and CD3, comprising one or two antigen binding moieties that specifically bind to GPRC5D and one or two antigen binding moieties that specifically bind to CD3, the antigen binding moiety that specifically binds to GPRC5D comprises a heavy chain variable region GPRC5D-VH and a light chain variable region GPRC5D-VL, and the antigen binding moiety that specifically binds to CD3 comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL.

[0009] In one aspect, the present disclosure provides an antigen binding molecule that specifically binds to GPRC5D and CD3, comprising an antigen binding moiety that specifically binds to GPRC5D and an antigen binding moiety that specifically binds to CD3, wherein the antigen binding moiety that specifically binds to GPRC5D comprises a heavy chain variable region GPRC5D-VH and a light chain variable region GPRC5D-VL, and the antigen binding moiety that specifically binds to CD3 comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL.

[0010] In one aspect, the present disclosure provides an antigen binding molecule that specifically binds to GPRC5D and CD3, comprising two antigen binding moieties that specifically bind to GPRC5D and two antigen binding moieties that specifically bind to CD3, wherein the antigen binding moieties that specifically bind to GPRC5D comprise a heavy chain variable region GPRC5D-VH and a light chain variable region GPRC5D-VL, and the antigen binding moieties that specifically bind to CD3 comprise a heavy chain variable region CD3-VH and a light chain variable region CD3-VL.

[0011] In the embodiments of the antigen binding molecules that specifically bind to GPRC5D and CD3 provided by the present disclosure, the antigen binding moiety that specifically binds to GPRC5D can be a Fab, which comprises a heavy chain variable region GPRC5D-VH, a heavy chain constant region CH1, a light chain variable region GPRC5D-VL and a light chain constant region CL.

[0012] In the embodiments of the antigen binding molecules that specifically bind to GPRC5D and CD3 provided by the present disclosure, the antigen binding moiety that specifically binds to CD3 can be a replaced Fab comprising a heavy chain variable region CD3-VH, an obscurin chain, a light chain variable region CD3-VL and a titin chain.

[0013] In the embodiments of the antigen binding molecules specifically binding to GPRC5D and CD3 provided by the present disclosure, the antigen binding moiety that specifically binds to CD3 may be a scFv comprising a heavy chain variable region CD3-VH and a light chain variable region CD3-VL.

[0014] In some embodiments, the antigen binding molecule as described above, wherein:

[0015] (i) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 137, 18, 135, 136 or 138, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or

[0016] (ii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, 10 or 133, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, 12, 129, 131 or 132, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0017] (iii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 21, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 140, 22 or 139, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 23, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 25, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 26; or

[0018] (iv) the GPRC5D-VH comprises: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 27, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 29, and the GPRC5D-VL comprises: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 144, 30, 141, 142 or 143, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.

[0019] In some embodiments, the GPRC5D-HCDR1, GPRC5D-HCDR2, GPRC5D-HCDR3, GPRC5D-LCDR1, GPRC5D-LCDR2, and GPRC5D-LCDR3 are defined according to Kabat, IMGT, Chothia, AbM, or Contact numbering conventions.

[0020] In some embodiments, the antigen binding molecule as described above, wherein:

[0021] (i) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 137, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or

[0022] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 18, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or

[0023] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 138, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or

[0024] (ii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0025] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0026] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0027] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0028] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0029] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0030] (iii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 21, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 140, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 23, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 25, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 26; or

[0031] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 21, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 139, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 23, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 25, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 26; or

[0032] (iv) the GPRC5D-VH comprises: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 27, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 29, and the GPRC5D-VL comprises: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.

[0033] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein:

[0034] (i) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 137, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or

[0035] (ii) the GPRC5D-VH comprises: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprises: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14.

[0036] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein:

[0037] The GPRC5D-VH comprises GPRC5D-HCDR1: its amino acid sequence is shown in SEQ ID NO: 9, GPRC5D-HCDR2: its amino acid sequence is shown in SEQ ID NO: 134 and GPRC5D-HCDR3: its amino acid sequence is shown in SEQ ID NO: 11, and the GPRC5D-VL comprises GPRC5D-LCDR1: its amino acid sequence is shown in SEQ ID NO: 130, GPRC5D-LCDR2: its amino acid sequence is shown in SEQ ID NO: 13 and GPRC5D-LCDR3: its amino acid sequence is shown in SEQ ID NO: 14.

[0038] In embodiments of the antigen binding molecules of the present disclosure that specifically bind GPRC5D and CD3, wherein:

[0039] (i) the GPRC5D-VH comprises GPRC5D-HCDR1 shown in SEQ ID NO: 15, GPRC5D-HCDR2 shown in SEQ ID NO: 16, and GPRC5D-HCDR3 shown in SEQ ID NO: 17, and

[0040] The GPRC5D-VL comprises GPRC5D-LCDR1 shown in SEQ ID NO: 137, 18, 135, 136 or 138, GPRC5D-LCDR2 shown in SEQ ID NO: 19 and GPRC5D-LCDR3 shown in SEQ ID NO: 20; or

[0041] (ii) the GPRC5D-VH comprises the GPRC5D-HCDR1 shown in SEQ ID NO: 9, the GPRC5D-HCDR2 shown in SEQ ID NO: 134, 10 or 133, and the GPRC5D-HCDR3 shown in SEQ ID NO: 11, and

[0042] The GPRC5D-VL comprises GPRC5D-LCDR1 shown in SEQ ID NO: 130, 12, 129, 131 or 132, GPRC5D-LCDR2 shown in SEQ ID NO: 13 and GPRC5D-LCDR3 shown in SEQ ID NO: 14; or

[0043] (iii) the GPRC5D-VH comprises the GPRC5D-HCDR1 shown in SEQ ID NO: 21, the GPRC5D-HCDR2 shown in SEQ ID NO: 140, 22 or 139, and the GPRC5D-HCDR3 shown in SEQ ID NO: 23, and

[0044] The GPRC5D-VL comprises GPRC5D-LCDR1 shown in SEQ ID NO: 24, GPRC5D-LCDR2 shown in SEQ ID NO: 25, and GPRC5D-LCDR3 shown in SEQ ID NO: 26; or

[0045] (iv) the GPRC5D-VH comprises GPRC5D-HCDR1 shown in SEQ ID NO: 27, GPRC5D-HCDR2 shown in SEQ ID NO: 28, and GPRC5D-HCDR3 shown in SEQ ID NO: 29, and

[0046] The GPRC5D-VL comprises the GPRC5D-LCDR1 shown in SEQ ID NO: 144, 30, 141, 142 or 143, the GPRC5D-LCDR2 shown in SEQ ID NO: 31 and the GPRC5D-LCDR3 shown in SEQ ID NO: 32;

[0047] Preferably,

[0048] (i) the GPRC5D-VH comprises GPRC5D-HCDR1 shown in SEQ ID NO: 15, GPRC5D-HCDR2 shown in SEQ ID NO: 16, and GPRC5D-HCDR3 shown in SEQ ID NO: 17, and

[0049] The GPRC5D-VL comprises GPRC5D-LCDR1 shown in SEQ ID NO: 137, GPRC5D-LCDR2 shown in SEQ ID NO: 19, and GPRC5D-LCDR3 shown in SEQ ID NO: 20; or

[0050] (ii) the GPRC5D-VH comprises the GPRC5D-HCDR1 shown in SEQ ID NO: 9, the GPRC5D-HCDR2 shown in SEQ ID NO: 134, and the GPRC5D-HCDR3 shown in SEQ ID NO: 11, and

[0051] The GPRC5D-VL comprises the GPRC5D-LCDR1 shown in SEQ ID NO: 130, the GPRC5D-LCDR2 shown in SEQ ID NO: 13, and the GPRC5D-LCDR3 shown in SEQ ID NO: 14.

[0052] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein:

[0053] The GPRC5D-VH comprises GPRC5D-HCDR1: its amino acid sequence is shown in SEQ ID NO: 15, GPRC5D-HCDR2: its amino acid sequence is shown in SEQ ID NO: 16 and GPRC5D-HCDR3: its amino acid sequence is shown in SEQ ID NO: 17, and the GPRC5D-VL comprises GPRC5D-LCDR1: its amino acid sequence is shown in SEQ ID NO: 137, GPRC5D-LCDR2: its amino acid sequence is shown in SEQ ID NO: 19 and GPRC5D-LCDR3: its amino acid sequence is shown in SEQ ID NO: 20.

[0054] In some embodiments, the GPRC5D-HCDR1, GPRC5D-HCDR2, GPRC5D-HCDR3, GPRC5D-LCDR1, GPRC5D-LCDR2, and GPRC5D-LCDR3 are defined according to the Kabat numbering convention.

[0055] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein:

[0056] (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, 3, 42 or 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49, 4, 45, 46, 47, 48 or 50; or

[0057] (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, 1, 33 or 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39, 2, 36, 37, 38, 40 or 41; or

[0058] (iii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, 5, 51, 52, 53 or 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56, 6 or 57; or

[0059] (iv) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 67, 7, 58, 59, 60, 61, 62, 63, 64, 65, 66 or 68, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75, 8, 69, 70, 71, 72, 73 or 74.

[0060] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein:

[0061] (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or

[0062] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 46; or

[0063] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or

[0064] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 50; or

[0065] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 46; or

[0066] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 50; or

[0067] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 3, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 4; or

[0068] (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39; or

[0069] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 36; or

[0070] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 38; or

[0071] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39; or

[0072] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 36; or

[0073] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 38; or

[0074] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 1, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 2; or

[0075] (iii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56; or

[0076] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56; or

[0077] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 57; or

[0078] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 57; or

[0079] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 5, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 6; or

[0080] (iv) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 67, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or

[0081] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 61, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or

[0082] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 62, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or

[0083] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 64, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or

[0084] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 65, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or

[0085] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 7, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 8.

[0086] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein:

[0087] (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or

[0088] (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39; or

[0089] (iii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56; or

[0090] (iv) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 67, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75.

[0091] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein:

[0092] (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or

[0093] (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39.

[0094] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein:

[0095] The amino acid sequence of the GPRC5D-VH is shown in SEQ ID NO: 35, and the amino acid sequence of the GPRC5D-VL is shown in SEQ ID NO: 39.

[0096] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein:

[0097] The amino acid sequence of the GPRC5D-VH is shown in SEQ ID NO: 44, and the amino acid sequence of the GPRC5D-VL is shown in SEQ ID NO: 49.

[0098] In an embodiment of the antigen binding molecule of the present disclosure that specifically binds to GPRC5D and CD3, the antigen binding moiety that specifically binds to GPRC5D comprises:

[0099] (i) GPRC5D-VH set forth in SEQ ID NO: 44, 3, 42, or 43, and GPRC5D-VL set forth in SEQ ID NO: 49, 4, 45, 46, 47, 48, or 50; or

[0100] (ii) GPRC5D-VH set forth in SEQ ID NO: 35, 1, 33, or 34, and GPRC5D-VL set forth in SEQ ID NO: 39, 2, 36, 37, 38, 40, or 41; or

[0101] (iii) GPRC5D-VH set forth in SEQ ID NO: 55, 5, 51, 52, 53, or 54, and GPRC5D-VL set forth in SEQ ID NO: 56, 6, or 57; or

[0102] (iv) GPRC5D-VH set forth in SEQ ID NO: 67, 7, 58, 59, 60, 61, 62, 63, 64, 65, 66, or 68, and GPRC5D-VL set forth in SEQ ID NO: 75, 8, 69, 70, 71, 72, 73, or 74;

[0103] Preferably,

[0104] (i) GPRC5D-VH shown in SEQ ID NO: 44, and GPRC5D-VL shown in SEQ ID NO: 49; or

[0105] GPRC5D-VH shown in SEQ ID NO: 43, and GPRC5D-VL shown in SEQ ID NO: 46; or

[0106] GPRC5D-VH shown in SEQ ID NO: 43, and GPRC5D-VL shown in SEQ ID NO: 49; or

[0107] GPRC5D-VH shown in SEQ ID NO:43, and GPRC5D-VL shown in SEQ ID NO:50; or

[0108] GPRC5D-VH shown in SEQ ID NO: 44, and GPRC5D-VL shown in SEQ ID NO: 46; or

[0109] GPRC5D-VH shown in SEQ ID NO:44, and GPRC5D-VL shown in SEQ ID NO:50; or

[0110] GPRC5D-VH shown in SEQ ID NO: 3, and GPRC5D-VL shown in SEQ ID NO: 4; or

[0111] (ii) GPRC5D-VH shown in SEQ ID NO: 35, and GPRC5D-VL shown in SEQ ID NO: 39; or

[0112] GPRC5D-VH shown in SEQ ID NO: 34, and GPRC5D-VL shown in SEQ ID NO: 36; or

[0113] GPRC5D-VH shown in SEQ ID NO: 34, and GPRC5D-VL shown in SEQ ID NO: 38; or

[0114] GPRC5D-VH shown in SEQ ID NO: 34, and GPRC5D-VL shown in SEQ ID NO: 39; or

[0115] GPRC5D-VH shown in SEQ ID NO: 35, and GPRC5D-VL shown in SEQ ID NO: 36; or

[0116] GPRC5D-VH shown in SEQ ID NO: 35, and GPRC5D-VL shown in SEQ ID NO: 38; or

[0117] GPRC5D-VH shown in SEQ ID NO: 1, and GPRC5D-VL shown in SEQ ID NO: 2; or

[0118] (iii) GPRC5D-VH shown in SEQ ID NO: 55, and GPRC5D-VL shown in SEQ ID NO: 56; or

[0119] GPRC5D-VH shown in SEQ ID NO: 54, and GPRC5D-VL shown in SEQ ID NO: 56; or

[0120] GPRC5D-VH shown in SEQ ID NO: 54, and GPRC5D-VL shown in SEQ ID NO: 57; or

[0121] GPRC5D-VH shown in SEQ ID NO: 55, and GPRC5D-VL shown in SEQ ID NO: 57; or

[0122] GPRC5D-VH shown in SEQ ID NO: 5, and GPRC5D-VL shown in SEQ ID NO: 6; or

[0123] (iv) GPRC5D-VH shown in SEQ ID NO: 67, and GPRC5D-VL shown in SEQ ID NO: 75; or

[0124] GPRC5D-VH shown in SEQ ID NO: 61, and GPRC5D-VL shown in SEQ ID NO: 75; or

[0125] GPRC5D-VH shown in SEQ ID NO: 62, and GPRC5D-VL shown in SEQ ID NO: 75; or

[0126] GPRC5D-VH shown in SEQ ID NO: 64, and GPRC5D-VL shown in SEQ ID NO: 75; or

[0127] GPRC5D-VH shown in SEQ ID NO: 65, and GPRC5D-VL shown in SEQ ID NO: 75; or

[0128] GPRC5D-VH shown in SEQ ID NO: 7, and GPRC5D-VL shown in SEQ ID NO: 8; or

[0129] More preferably, the antigen binding moiety that specifically binds to GPRC5D comprises:

[0130] (i) GPRC5D-VH shown in SEQ ID NO: 44, and GPRC5D-VL shown in SEQ ID NO: 49; or

[0131] (ii) GPRC5D-VH shown in SEQ ID NO: 35, and GPRC5D-VL shown in SEQ ID NO: 39.

[0132] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the antigen binding molecule further comprises an Fc region, and the Fc region is preferably an IgG Fc region, more preferably an IgG1 Fc region. In some embodiments, the Fc region comprises one or more amino acid substitutions compared to the wild-type Fc region, and the amino acid substitutions can reduce binding to Fc receptors, in particular binding to Fcγ receptors. In some embodiments, the Fc region comprises one or more amino acid substitutions that can reduce binding of the Fc region to Fcγ receptors. In some embodiments, the Fc region is a human IgG1 Fc region, and the amino acid residues at positions 234 and 235 are A, and the numbering is based on the EU index. In some embodiments, the Fc region comprises the amino acid sequence of SEQ ID NO: 97.

[0133] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the antigen binding molecule comprises an Fc region, the Fc region comprising a first subunit (Fc1) and a second subunit (Fc2) capable of associating with each other, the Fc1 and Fc2 each independently having one or more amino acid substitutions that reduce homodimerization of the Fc region. In some embodiments, the Fc1 and Fc2 each independently have one or more amino acid substitutions according to the pestle-and-mortar technique. In some embodiments, the Fc1 has a protrusion structure according to the pestle-and-mortar technique, and the Fc2 has a hole structure according to the pestle-and-mortar technique, or the Fc1 has a hole structure according to the pestle-and-mortar technique, and the Fc2 has a protrusion structure according to the pestle-and-mortar technique; preferably, the Fc1 has a protrusion structure according to the pestle-and-mortar technique, and the Fc2 has a hole structure according to the pestle-and-mortar technique. In some embodiments, the amino acid at position 366 of Fc1 is W; and the amino acid at position 366 of Fc2 is S, the amino acid at position 368 is A, and the amino acid at position 407 is V, numbering according to the EU index, or vice versa. In some embodiments, the amino acid at position 354 of Fc1 is C; and the amino acid at position 349 of Fc2 is C, numbering according to the EU index, or vice versa. In some embodiments, the amino acid at position 354 of Fc1 is C, the amino acid at position 366 is W; and the amino acid at position 349 of Fc2 is C, the amino acid at position 366 is S, the amino acid at position 368 is A, and the amino acid at position 407 is V, numbering according to the EU index, or vice versa. In some embodiments, the Fc1 has the amino acid sequence of SEQ ID NO: 92, and the Fc2 has the amino acid sequence of SEQ ID NO: 93.

[0134] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the antigen binding molecule comprises one or two antigen binding moieties that specifically bind to GPRC5D and one or two antigen binding moieties that specifically bind to CD3. In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the antigen binding molecule comprises one antigen binding moiety that specifically binds to GPRC5D and one antigen binding moiety that specifically binds to CD3. In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the antigen binding molecule comprises two antigen binding moieties that specifically bind to GPRC5D and two antigen binding moieties that specifically bind to CD3.

[0135] In some embodiments, the antigen binding molecule described in any of the preceding items, wherein the antigen binding moiety that specifically binds to GPRC5D is a Fab; the antigen binding moiety that specifically binds to CD3 is a replaced Fab or scFv. In some embodiments, the antigen binding molecule described in any of the preceding items, wherein the antigen binding moiety that specifically binds to GPRC5D is a Fab; the antigen binding moiety that specifically binds to CD3 is a replaced Fab. In some embodiments, the antigen binding molecule described in any of the preceding items, wherein the antigen binding moiety that specifically binds to GPRC5D is a Fab; the antigen binding moiety that specifically binds to CD3 is an scFv. In some embodiments, the replaced Fab is a Fab in which the original CH1 and CL are replaced by an obscurin chain and a titin chain, respectively, or a Fab in which the original CH1 and CL are replaced by a titin chain and an obscurin chain, respectively.

[0136] In some embodiments, the antigen binding molecule of any of the preceding items, wherein the antigen binding moiety that specifically binds to GPRC5D or the antigen binding moiety that specifically binds to CD3 comprises a titin chain and an obscurin chain that are capable of forming a dimer. In some embodiments, the titin chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 145 to SEQ ID NO: 163, and the obscurin chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 164 to SEQ ID NO: 204. In some embodiments, the titin chain comprises the amino acid sequence of SEQ ID NO: 163 or 161, and the obscurin chain comprises the amino acid sequence of SEQ ID NO: 198 or 199. In some embodiments, the titin chain comprises the amino acid sequence of SEQ ID NO: 163, and the obscurin chain comprises the amino acid sequence of SEQ ID NO: 198. In some embodiments, the titin chain comprises the amino acid sequence of SEQ ID NO: 161, and the obscurin chain comprises the amino acid sequence of SEQ ID NO: 199.

[0137] In some embodiments, the antigen binding molecule comprises an antigen binding moiety that specifically binds to GPRC5D and an antigen binding moiety that specifically binds to CD3, wherein the antigen binding moiety that specifically binds to GPRC5D is Fab; the antigen binding moiety that specifically binds to CD3 is a replaced Fab, which comprises a titin chain and an obscurin chain that can form a dimer. Preferably, the replaced Fab is a Fab in which the original CH1 and CL are replaced by the obscurin chain and the titin chain, respectively, or the original CH1 and CL of the Fab are replaced by the titin chain and the obscurin chain, respectively.

[0138] In some embodiments, at least one antigen binding moiety that specifically binds GPRC5D and at least one antigen binding moiety that specifically binds CD3 are linked to the N-terminus of the Fc1 or Fc2 subunit directly or through a linker via the C-terminus of the CH1 or Obscurin chain, and associate into a heterodimer via a disulfide bond at the N-termini of the Fc1 and Fc2 subunits.

[0139] In some embodiments, the antigen-binding molecule comprises a first chain having a structure as shown in formula (a), a second chain having a structure as shown in formula (b), a third chain having a structure as shown in formula (c), and a fourth chain having a structure as shown in formula (d).

[0140] (a) [GPRC5D-VH]-[CH1]-[Fc1],

[0141] (b) [GPRC5D-VL]-CL,

[0142] (c) [CD3-VH]-[Obscurin chain]-[Fc2],

[0143] (d) [CD3-VL]-[Titin chain],

[0144] The structures shown in formulas (a), (b), (c) and (d) are arranged from the N-terminus to the C-terminus.

[0145] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 35; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 39; the Obscurin chain in the third chain comprises the amino acid sequence of SEQ ID NO: 198; and the Titin chain in the fourth chain comprises the amino acid sequence of SEQ ID NO: 163.

[0146] In some embodiments, the antigen binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 118, a second chain comprising the amino acid sequence of SEQ ID NO: 102, a third chain comprising the amino acid sequence of SEQ ID NO: 86, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 87.

[0147] In some embodiments, the antigen binding molecule comprises a first chain having a structure represented by formula (e), a second chain having a structure represented by formula (d), a third chain having a structure represented by formula (f), and a fourth chain having a structure represented by formula (b).

[0148] (e)[CD3-VH]-[Obscurin chain]-[Fc1],

[0149] (d) [CD3-VL]-[Titin chain],

[0150] (f) [GPRC5D-VH]-[CH1]-[Fc2],

[0151] (b) [GPRC5D-VL]-CL,

[0152] The structures shown in formulas (e), (d), (f) and (b) are arranged from the N-terminus to the C-terminus.

[0153] In some embodiments, in the antigen binding molecule as described above, the Obscurin chain in the first chain comprises the amino acid sequence of SEQ ID NO: 198; the Titin chain in the second chain comprises the amino acid sequence of SEQ ID NO: 163; the GPRC5D-VH in the third chain comprises the amino acid sequence of SEQ ID NO: 44; and the GPRC5D-VL in the fourth chain comprises the amino acid sequence of SEQ ID NO: 49.

[0154] In some embodiments, the antigen binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 89, a second chain comprising the amino acid sequence of SEQ ID NO: 87, a third chain comprising the amino acid sequence of SEQ ID NO: 121, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 106.

[0155] In some embodiments, the antigen-binding molecule comprises a first chain having a structure as shown in formula (a), a second chain having a structure as shown in formula (b), a third chain having a structure as shown in formula (g), and a fourth chain having a structure as shown in formula (h).

[0156] (a) [GPRC5D-VH]-[CH1]-[Fc1],

[0157] (b) [GPRC5D-VL]-CL,

[0158] (g) [CD3-VH]-Linker 1-[Obscurin chain]-[Fc2],

[0159] (h) [CD3-VL]-Linker 2-[Titin chain],

[0160] The structures represented by formulas (a), (b), (g) and (h) are arranged from the N-terminus to the C-terminus, and the linker 1 and linker 2 are the same or different peptide linkers.

[0161] In some embodiments, the antigen binding molecule as described above, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 35, 44, 55, or 67; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 39, 49, 56, or 75; the Obscurin chain in the third chain comprises the amino acid sequence of SEQ ID NO: 199; and the Titin chain in the fourth chain comprises the amino acid sequence of SEQ ID NO: 161. In some embodiments, Linker 1 and / or Linker 2 comprises the amino acid sequence of (GGGGS)n, wherein n is 1-5; preferably, n is 1, 2, or 3; most preferably, n is 1.

[0162] In some embodiments, the antigen binding molecule of any of the preceding items, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 35; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 39; the Obscurin chain in the third chain comprises the amino acid sequence of SEQ ID NO: 199; the Titin chain in the fourth chain comprises the amino acid sequence of SEQ ID NO: 161; and the amino acid sequences of Linker 1 and Linker 2 are as shown in SEQ ID NO: 90. In some embodiments, the antigen binding molecule of any of the preceding items, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 44; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 49; the Obscurin chain in the third chain comprises the amino acid sequence of SEQ ID NO: 199; the Titin chain in the fourth chain comprises the amino acid sequence of SEQ ID NO: 161; and the amino acid sequences of Linker 1 and Linker 2 are as shown in SEQ ID NO: 90. In some embodiments, the antigen binding molecule of any of the preceding items, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 55; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 56; the Obscurin chain in the third chain comprises the amino acid sequence of SEQ ID NO: 199; the Titin chain in the fourth chain comprises the amino acid sequence of SEQ ID NO: 161; and the amino acid sequences of Linker 1 and Linker 2 are as shown in SEQ ID NO: 90. In some embodiments, the antigen binding molecule of any of the preceding items, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 67; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 75; the Obscurin chain in the third chain comprises the amino acid sequence of SEQ ID NO: 199; the Titin chain in the fourth chain comprises the amino acid sequence of SEQ ID NO: 161; and the amino acid sequences of Linker 1 and Linker 2 are as shown in SEQ ID NO: 90.

[0163] In some embodiments, the antigen binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 118, a second chain comprising the amino acid sequence of SEQ ID NO: 102, a third chain comprising the amino acid sequence of SEQ ID NO: 84, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 85; or

[0164] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 120, a second chain comprising the amino acid sequence of SEQ ID NO: 106, a third chain comprising the amino acid sequence of SEQ ID NO: 84, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 85; or

[0165] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 122, a second chain comprising the amino acid sequence of SEQ ID NO: 110, a third chain comprising the amino acid sequence of SEQ ID NO: 84, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 85; or

[0166] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 124, a second chain comprising the amino acid sequence of SEQ ID NO: 117, a third chain comprising the amino acid sequence of SEQ ID NO: 84, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 85.

[0167] In some embodiments, the antigen-binding molecule comprises a first chain having a structure as shown in formula (i), a second chain having a structure as shown in formula (j), a third chain having a structure as shown in formula (f), and a fourth chain having a structure as shown in formula (b).

[0168] (i) [CD3-VH]-Linker 3-[Obscurin chain]-[Fc1],

[0169] (j) [CD3-VL]-Linker 4-[Titin chain],

[0170] (f) [GPRC5D-VH]-[CH1]-[Fc2],

[0171] (b) [GPRC5D-VL]-CL,

[0172] The structures represented by formulas (i), (j), (f) and (b) are arranged from the N-terminus to the C-terminus, and the linker 3 and the linker 4 are the same or different peptide linkers.

[0173] In some embodiments, in the antigen binding molecule as described above, the Obscurin chain in the first chain comprises the amino acid sequence of SEQ ID NO: 199; the Titin chain in the second chain comprises the amino acid sequence of SEQ ID NO: 161; the GPRC5D-VH in the third chain comprises the amino acid sequence of SEQ ID NO: 35, 44, 55, 61, 62, 64, 65, or 67; and the GPRC5D-VL in the fourth chain comprises the amino acid sequence of SEQ ID NO: 39, 49, 56, or 75. In some embodiments, Linker 3 and / or Linker 4 comprises an amino acid sequence of (GGGGS)n, wherein n is 1-5; preferably, n is 1, 2, or 3; most preferably, n is 1.

[0174] In some embodiments, the antigen binding molecule of any of the preceding items, wherein the Obscurin chain in the first chain comprises the amino acid sequence of SEQ ID NO: 199; the Titin chain in the second chain comprises the amino acid sequence of SEQ ID NO: 161; the GPRC5D-VH in the third chain comprises the amino acid sequence of SEQ ID NO: 35; the GPRC5D-VL in the fourth chain comprises the amino acid sequence of SEQ ID NO: 39; and the amino acid sequences of Linker 3 and Linker 4 are as shown in SEQ ID NO: 90. In some embodiments, the antigen binding molecule of any of the preceding items, wherein the Obscurin chain in the first chain comprises the amino acid sequence of SEQ ID NO: 199; the Titin chain in the second chain comprises the amino acid sequence of SEQ ID NO: 161; the GPRC5D-VH in the third chain comprises the amino acid sequence of SEQ ID NO: 44; the GPRC5D-VL in the fourth chain comprises the amino acid sequence of SEQ ID NO: 49; and the amino acid sequences of Linker 3 and Linker 4 are as shown in SEQ ID NO: 90. In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the Obscurin chain in the first chain comprises the amino acid sequence of SEQ ID NO: 199; the Titin chain in the second chain comprises the amino acid sequence of SEQ ID NO: 161; the GPRC5D-VH in the third chain comprises the amino acid sequence of SEQ ID NO: 55; the GPRC5D-VL in the fourth chain comprises the amino acid sequence of SEQ ID NO: 56; and the amino acid sequences of Linker 3 and Linker 4 are shown in SEQ ID NO: 90. In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the Obscurin chain in the first chain comprises the amino acid sequence of SEQ ID NO: 199; the Titin chain in the second chain comprises the amino acid sequence of SEQ ID NO: 161; the GPRC5D-VH in the third chain comprises the amino acid sequence of SEQ ID NO: 61, 62, 64, 65 or 67; the GPRC5D-VL in the fourth chain comprises the amino acid sequence of SEQ ID NO: 75; and the amino acid sequences of Linker 3 and Linker 4 are shown in SEQ ID NO: 90.

[0175] In some embodiments, the antigen binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 116, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 117; or

[0176] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 121, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 106; or

[0177] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 123, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 110; or

[0178] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 119, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 102; or

[0179] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 115, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 117; or

[0180] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 112, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 117; or

[0181] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 113, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 117; or

[0182] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 114, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 117; or

[0183] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 227, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 223.

[0184] In some embodiments, the antigen binding molecule comprises two antigen binding moieties that specifically bind to GPRC5D and two antigen binding moieties that specifically bind to CD3, the antigen binding moieties that specifically bind to GPRC5D are Fabs; and the antigen binding moieties that specifically bind to CD3 are scFvs.

[0185] In some embodiments, the antigen binding molecule comprises two first chains having a structure represented by formula (k) and two second chains having a structure represented by formula (b).

[0186] (k) [GPRC5D-VH]-[CH1]-[CD3-VH]-Linker 5-[CD3-VL]-Linker 6-[Fc3],

[0187] (b) [GPRC5D-VL]-CL,

[0188] The structures shown in formula (k) and (b) are arranged from the N-terminus to the C-terminus, and the linker 5 and the linker 6 are the same or different peptide linkers.

[0189] In some embodiments, the antigen binding molecule as described above, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 35, 34, 44, 43, 55 or 54; and the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 39, 36, 38, 49, 46, 50, 56 or 57. In some embodiments, linker 5 and / or linker 6 comprises an amino acid sequence of (GGGGS)n, wherein n is 1-5; preferably, n is 1, 2 or 3; most preferably, n is 1 or 3.

[0190] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 35 or 34; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 39, 36 or 38; the amino acid sequence of Linker 5 is shown in SEQ ID NO: 94; and the amino acid sequence of Linker 6 is shown in SEQ ID NO: 95. In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 44 or 43; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 49, 46 or 50; the amino acid sequence of Linker 5 is shown in SEQ ID NO: 94; and the amino acid sequence of Linker 6 is shown in SEQ ID NO: 95. In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 55 or 54; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 56 or 57; the amino acid sequence of linker 5 is shown in SEQ ID NO: 94; and the amino acid sequence of linker 6 is shown in SEQ ID NO: 95.

[0191] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 35; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 39; the amino acid sequence of linker 5 is shown in SEQ ID NO: 94; and the amino acid sequence of linker 6 is shown in SEQ ID NO: 95.

[0192] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 44; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 49; the amino acid sequence of linker 5 is shown in SEQ ID NO: 94; and the amino acid sequence of linker 6 is shown in SEQ ID NO: 95.

[0193] In some embodiments, the antigen binding molecule as described in any of the preceding items, wherein the GPRC5D-VH in the first chain comprises the amino acid sequence of SEQ ID NO: 55; the GPRC5D-VL in the second chain comprises the amino acid sequence of SEQ ID NO: 56; the amino acid sequence of linker 5 is as shown in SEQ ID NO: 94; and the amino acid sequence of linker 6 is as shown in SEQ ID NO: 95.

[0194] In some embodiments, the antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 98 and two second chains comprising the amino acid sequence of SEQ ID NO: 100; or

[0195] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 98 and two second chains comprising the amino acid sequence of SEQ ID NO: 101; or

[0196] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 98 and two second chains comprising the amino acid sequence of SEQ ID NO: 102; or

[0197] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 99 and two second chains comprising the amino acid sequence of SEQ ID NO: 100; or

[0198] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 99 and two second chains comprising the amino acid sequence of SEQ ID NO: 101; or

[0199] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 99 and two second chains comprising the amino acid sequence of SEQ ID NO: 102; or

[0200] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 103 and two second chains comprising the amino acid sequence of SEQ ID NO: 105; or

[0201] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 103 and two second chains comprising the amino acid sequence of SEQ ID NO: 106; or

[0202] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 103 and two second chains comprising the amino acid sequence of SEQ ID NO: 107; or

[0203] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 104 and two second chains comprising the amino acid sequence of SEQ ID NO: 105; or

[0204] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 104 and two second chains comprising the amino acid sequence of SEQ ID NO: 106; or

[0205] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 104 and two second chains comprising the amino acid sequence of SEQ ID NO: 107; or

[0206] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 108 and two second chains comprising the amino acid sequence of SEQ ID NO: 110; or

[0207] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 109 and two second chains comprising the amino acid sequence of SEQ ID NO: 110; or

[0208] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 108 and two second chains comprising the amino acid sequence of SEQ ID NO: 111; or

[0209] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 109 and two second chains comprising the amino acid sequence of SEQ ID NO: 111; or

[0210] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 224 and two second chains comprising the amino acid sequence of SEQ ID NO: 217; or

[0211] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 225 and two second chains comprising the amino acid sequence of SEQ ID NO: 219; or

[0212] The antigen-binding molecule comprises: two first chains comprising the amino acid sequence of SEQ ID NO: 226 and two second chains comprising the amino acid sequence of SEQ ID NO: 221.

[0213] In another aspect, the present disclosure also provides an isolated antibody that can specifically bind to GPRC5D, the isolated antibody comprising a heavy chain variable region GPRC5D-VH and a light chain variable region GPRC5D-VL, wherein (i) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 137, 18, 135, 136 or 138, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or

[0214] (ii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, 10 or 133, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, 12, 129, 131 or 132, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0215] (iii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 21, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 140, 22 or 139, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 23, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 25, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 26; or

[0216] (iv) the GPRC5D-VH comprises: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 27, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 29, and the GPRC5D-VL comprises: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 144, 30, 141, 142 or 143, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.

[0217] In some embodiments, the GPRC5D-HCDR1, GPRC5D-HCDR2, GPRC5D-HCDR3, GPRC5D-LCDR1, GPRC5D-LCDR2, and GPRC5D-LCDR3 are defined according to Kabat, IMGT, Chothia, AbM, or Contact numbering conventions.

[0218] In some embodiments, the isolated antibody as described above, wherein:

[0219] (i) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 137, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or

[0220] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 18, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or

[0221] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 138, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or

[0222] (ii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0223] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0224] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0225] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0226] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0227] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or

[0228] (iii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 21, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 140, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 23, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 25, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 26; or

[0229] the GPRC5D-VH comprising: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 21, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 139, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 23, and the GPRC5D-VL comprising: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 25, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 26; or

[0230] (iv) the GPRC5D-VH comprises: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 27, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 29, and the GPRC5D-VL comprises: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.

[0231] In some embodiments, the isolated antibody as described above, wherein:

[0232] (i) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 137, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or

[0233] (ii) the GPRC5D-VH comprises: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprises: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14.

[0234] In some embodiments, an isolated antibody is provided that can specifically bind to GPRC5D, wherein the antibody comprises a heavy chain variable region GPRC5D-VH and a light chain variable region GPRC5D-VL, wherein:

[0235] (i) the GPRC5D-VH comprises GPRC5D-HCDR1 shown in SEQ ID NO: 15, GPRC5D-HCDR2 shown in SEQ ID NO: 16, and GPRC5D-HCDR3 shown in SEQ ID NO: 17, and

[0236] The GPRC5D-VL comprises GPRC5D-LCDR1 shown in SEQ ID NO: 137, 18, 135, 136 or 138, GPRC5D-LCDR2 shown in SEQ ID NO: 19 and GPRC5D-LCDR3 shown in SEQ ID NO: 20; or

[0237] (ii) the GPRC5D-VH comprises the GPRC5D-HCDR1 shown in SEQ ID NO: 9, the GPRC5D-HCDR2 shown in SEQ ID NO: 134, 10 or 133, and the GPRC5D-HCDR3 shown in SEQ ID NO: 11, and

[0238] The GPRC5D-VL comprises GPRC5D-LCDR1 shown in SEQ ID NO: 130, 12, 129, 131 or 132, GPRC5D-LCDR2 shown in SEQ ID NO: 13 and GPRC5D-LCDR3 shown in SEQ ID NO: 14; or

[0239] (iii) the GPRC5D-VH comprises the GPRC5D-HCDR1 shown in SEQ ID NO: 21, the GPRC5D-HCDR2 shown in SEQ ID NO: 140, 22 or 139, and the GPRC5D-HCDR3 shown in SEQ ID NO: 23, and

[0240] The GPRC5D-VL comprises GPRC5D-LCDR1 shown in SEQ ID NO: 24, GPRC5D-LCDR2 shown in SEQ ID NO: 25, and GPRC5D-LCDR3 shown in SEQ ID NO: 26; or

[0241] (iv) the GPRC5D-VH comprises GPRC5D-HCDR1 shown in SEQ ID NO: 27, GPRC5D-HCDR2 shown in SEQ ID NO: 28, and GPRC5D-HCDR3 shown in SEQ ID NO: 29, and

[0242] The GPRC5D-VL comprises the GPRC5D-LCDR1 shown in SEQ ID NO: 144, 30, 141, 142 or 143, the GPRC5D-LCDR2 shown in SEQ ID NO: 31 and the GPRC5D-LCDR3 shown in SEQ ID NO: 32;

[0243] Preferably,

[0244] (i) the GPRC5D-VH comprises the GPRC5D-HCDR1 shown in SEQ ID NO: 15, the GPRC5D-HCDR2 shown in SEQ ID NO: 16, and the GPRC5D-HCDR3 shown in SEQ ID NO: 17,

[0245] and the GPRC5D-VL comprises GPRC5D-LCDR1 shown in SEQ ID NO: 137, GPRC5D-LCDR2 shown in SEQ ID NO: 19, and GPRC5D-LCDR3 shown in SEQ ID NO: 20; or

[0246] (ii) the GPRC5D-VH comprises the GPRC5D-HCDR1 shown in SEQ ID NO: 9, the GPRC5D-HCDR2 shown in SEQ ID NO: 134, and the GPRC5D-HCDR3 shown in SEQ ID NO: 11,

[0247] The GPRC5D-VL comprises the GPRC5D-LCDR1 shown in SEQ ID NO: 130, the GPRC5D-LCDR2 shown in SEQ ID NO: 13, and the GPRC5D-LCDR3 shown in SEQ ID NO: 14.

[0248] In some embodiments, the isolated antibody as described above, wherein:

[0249] The GPRC5D-VH comprises GPRC5D-HCDR1, whose amino acid sequence is shown in SEQ ID NO: 9, GPRC5D-HCDR2, whose amino acid sequence is shown in SEQ ID NO: 134, and GPRC5D-HCDR3, whose amino acid sequence is shown in SEQ ID NO: 11, and the GPRC5D-VL comprises GPRC5D-LCDR1, whose amino acid sequence is shown in SEQ ID NO: 130, GPRC5D-LCDR2, whose amino acid sequence is shown in SEQ ID NO: 13, and GPRC5D-LCDR3, whose amino acid sequence is shown in SEQ ID NO: 14. In some embodiments, the isolated antibody as described above, wherein:

[0250] The GPRC5D-VH comprises GPRC5D-HCDR1: its amino acid sequence is shown in SEQ ID NO: 15, GPRC5D-HCDR2: its amino acid sequence is shown in SEQ ID NO: 16 and GPRC5D-HCDR3: its amino acid sequence is shown in SEQ ID NO: 17, and the GPRC5D-VL comprises GPRC5D-LCDR1: its amino acid sequence is shown in SEQ ID NO: 137, GPRC5D-LCDR2: its amino acid sequence is shown in SEQ ID NO: 19 and GPRC5D-LCDR3: its amino acid sequence is shown in SEQ ID NO: 20.

[0251] In some embodiments, the GPRC5D-HCDR1, GPRC5D-HCDR2, GPRC5D-HCDR3, GPRC5D-LCDR1, GPRC5D-LCDR2, and GPRC5D-LCDR3 are defined according to the Kabat numbering convention.

[0252] In some embodiments, the isolated antibody as described above, wherein:

[0253] (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, 3, 42 or 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49, 4, 45, 46, 47, 48 or 50; or

[0254] (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, 1, 33 or 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39, 2, 36, 37, 38, 40 or 41; or

[0255] (iii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, 5, 51, 52, 53 or 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56, 6 or 57; or

[0256] (iv) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 67, 7, 58, 59, 60, 61, 62, 63, 64, 65, 66 or 68, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75, 8, 69, 70, 71, 72, 73 or 74.

[0257] In some embodiments, the isolated antibody as described above, wherein:

[0258] (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or

[0259] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 46; or

[0260] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or

[0261] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 50; or

[0262] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 46; or

[0263] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 50; or

[0264] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 3, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 4; or

[0265] (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39; or

[0266] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 36; or

[0267] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 38; or

[0268] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39; or

[0269] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 36; or

[0270] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 38; or

[0271] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 1, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 2; or

[0272] (iii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56; or

[0273] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56; or

[0274] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 57; or

[0275] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 57; or

[0276] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 5, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 6; or

[0277] (iv) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 67, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or

[0278] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 61, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or

[0279] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 62, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or

[0280] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 64, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or

[0281] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 65, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or

[0282] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 7, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 8.

[0283] In some embodiments, the isolated antibody as described above, wherein:

[0284] (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or

[0285] (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39; or

[0286] (iii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56; or

[0287] (iv) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 67, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75.

[0288] In some embodiments, the isolated antibody as described above, wherein:

[0289] (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or

[0290] (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39.

[0291] In some embodiments, the isolated antibody as described above, wherein:

[0292] The amino acid sequence of the GPRC5D-VH is shown in SEQ ID NO: 35, and the amino acid sequence of the GPRC5D-VL is shown in SEQ ID NO: 39.

[0293] In some embodiments, the isolated antibody as described above, wherein:

[0294] The amino acid sequence of the GPRC5D-VH is shown in SEQ ID NO: 44, and the amino acid sequence of the GPRC5D-VL is shown in SEQ ID NO: 49.

[0295] In some embodiments, the isolated antibody comprises:

[0296] (i) GPRC5D-VH set forth in SEQ ID NO: 44, 3, 42, or 43, and GPRC5D-VL set forth in SEQ ID NO: 49, 4, 45, 46, 47, 48, or 50; or

[0297] (ii) GPRC5D-VH set forth in SEQ ID NO: 35, 1, 33, or 34, and GPRC5D-VL set forth in SEQ ID NO: 39, 2, 36, 37, 38, 40, or 41; or

[0298] (iii) GPRC5D-VH set forth in SEQ ID NO: 55, 5, 51, 52, 53, or 54, and GPRC5D-VL set forth in SEQ ID NO: 56, 6, or 57; or

[0299] (iv) GPRC5D-VH set forth in SEQ ID NO: 67, 7, 58, 59, 60, 61, 62, 63, 64, 65, 66, or 68, and GPRC5D-VL set forth in SEQ ID NO: 75, 8, 69, 70, 71, 72, 73, or 74;

[0300] Preferably, the antibody comprises:

[0301] (i) GPRC5D-VH shown in SEQ ID NO: 44, and GPRC5D-VL shown in SEQ ID NO: 49, or

[0302] GPRC5D-VH shown in SEQ ID NO: 43, and GPRC5D-VL shown in SEQ ID NO: 46, or

[0303] GPRC5D-VH shown in SEQ ID NO: 43, and GPRC5D-VL shown in SEQ ID NO: 49, or

[0304] GPRC5D-VH shown in SEQ ID NO: 43, and GPRC5D-VL shown in SEQ ID NO: 50, or

[0305] GPRC5D-VH shown in SEQ ID NO: 44, and GPRC5D-VL shown in SEQ ID NO: 46, or

[0306] GPRC5D-VH shown in SEQ ID NO:44, and GPRC5D-VL shown in SEQ ID NO:50; or

[0307] GPRC5D-VH shown in SEQ ID NO: 3, and GPRC5D-VL shown in SEQ ID NO: 4; or

[0308] (ii) GPRC5D-VH shown in SEQ ID NO: 35, and GPRC5D-VL shown in SEQ ID NO: 39; or

[0309] GPRC5D-VH shown in SEQ ID NO: 34, and GPRC5D-VL shown in SEQ ID NO: 36, or

[0310] GPRC5D-VH shown in SEQ ID NO: 34, and GPRC5D-VL shown in SEQ ID NO: 38, or

[0311] GPRC5D-VH shown in SEQ ID NO: 34, and GPRC5D-VL shown in SEQ ID NO: 39, or

[0312] GPRC5D-VH shown in SEQ ID NO: 35, and GPRC5D-VL shown in SEQ ID NO: 36, or

[0313] GPRC5D-VH shown in SEQ ID NO: 35, and GPRC5D-VL shown in SEQ ID NO: 38, or

[0314] GPRC5D-VH shown in SEQ ID NO: 1, and GPRC5D-VL shown in SEQ ID NO: 2; or

[0315] (iii) GPRC5D-VH shown in SEQ ID NO: 55, and GPRC5D-VL shown in SEQ ID NO: 56, or

[0316] GPRC5D-VH shown in SEQ ID NO: 54, and GPRC5D-VL shown in SEQ ID NO: 56, or

[0317] GPRC5D-VH shown in SEQ ID NO: 54, and GPRC5D-VL shown in SEQ ID NO: 57, or

[0318] GPRC5D-VH shown in SEQ ID NO: 55, and GPRC5D-VL shown in SEQ ID NO: 57; or

[0319] GPRC5D-VH shown in SEQ ID NO: 5, and GPRC5D-VL shown in SEQ ID NO: 6; or

[0320] (iv) GPRC5D-VH shown in SEQ ID NO: 67, and GPRC5D-VL shown in SEQ ID NO: 75, or

[0321] GPRC5D-VH shown in SEQ ID NO: 61, and GPRC5D-VL shown in SEQ ID NO: 75, or

[0322] GPRC5D-VH shown in SEQ ID NO: 62, and GPRC5D-VL shown in SEQ ID NO: 75, or

[0323] GPRC5D-VH shown in SEQ ID NO: 64, and GPRC5D-VL shown in SEQ ID NO: 75, or

[0324] GPRC5D-VH shown in SEQ ID NO: 65, and GPRC5D-VL shown in SEQ ID NO: 75; or

[0325] GPRC5D-VH shown in SEQ ID NO: 7, and GPRC5D-VL shown in SEQ ID NO: 8; or

[0326] More preferably, the antibody comprises:

[0327] (i) GPRC5D-VH shown in SEQ ID NO: 44, and GPRC5D-VL shown in SEQ ID NO: 49, or

[0328] (ii) GPRC5D-VH shown in SEQ ID NO: 35, and GPRC5D-VL shown in SEQ ID NO: 39.

[0329] In some embodiments, the antigen binding molecule of any of the preceding claims or the isolated antibody of any of the preceding claims is a bispecific antibody.

[0330] In some embodiments, the bispecific antibody specifically binds GPRC5D and CD3.

[0331] In some embodiments, the antigen binding molecule of any of the aforementioned or the isolated antibody of any of the aforementioned, wherein the antigen binding molecule or antibody does not bind to E2 peptide, E3 peptide and E4 peptide, wherein the E2 peptide comprises the amino acid sequence of SEQ ID NO: 206, the E3 peptide comprises the amino acid sequence of SEQ ID NO: 207, and the E4 peptide comprises the amino acid sequence of SEQ ID NO: 208.

[0332] In some embodiments, the antigen binding molecule of any preceding item or the isolated antibody of any preceding item binds to the amino terminal region of human GPRC5D, wherein the amino terminal region of human GPRC5D comprises the amino acid sequence of SEQ ID NO: 205.

[0333] In some embodiments, the antigen-binding molecule of any of the aforementioned items or the isolated antibody of any of the aforementioned items, wherein the antigen-binding molecule or antibody does not bind to the E2 peptide, E3 peptide, and E4 peptide, and binds to the amino-terminal region of human GPRC5D, wherein the E2 peptide comprises the amino acid sequence of SEQ ID NO: 206, the E3 peptide comprises the amino acid sequence of SEQ ID NO: 207, the E4 peptide comprises the amino acid sequence of SEQ ID NO: 208, and the amino-terminal region comprises the amino acid sequence of SEQ ID NO: 205.

[0334] In some embodiments, the antigen-binding molecule of any of the aforementioned items or the isolated antibody of any of the aforementioned items, wherein the antigen-binding molecule or antibody does not bind to E2 peptide, E3 peptide, and E4 peptide, and binds to the amino-terminal region of human GPRC5D, wherein the amino acid sequence of the E2 peptide is shown in SEQ ID NO: 206, the amino acid sequence of the E3 peptide is shown in SEQ ID NO: 207, the amino acid sequence of the E4 peptide is shown in SEQ ID NO: 208, and the amino acid sequence of the amino-terminal region is shown in SEQ ID NO: 205.

[0335] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: a therapeutically effective amount of any of the aforementioned antigen-binding molecules or any of the aforementioned isolated antibodies, and one or more pharmaceutically acceptable carriers, diluents, buffers, or excipients. In some embodiments, the pharmaceutical composition further comprises at least one second therapeutic agent.

[0336] In another aspect, the present disclosure also provides an isolated nucleic acid encoding any of the aforementioned antigen binding molecules or any of the aforementioned isolated antibodies.

[0337] In another aspect, the present disclosure also provides a host cell comprising the aforementioned nucleic acid.

[0338] In another aspect, the present disclosure also provides a method for treating a disease, comprising administering to a subject a therapeutically effective amount of any of the aforementioned antigen-binding molecules or any of the aforementioned isolated antibodies or compositions thereof.

[0339] In another aspect, the present disclosure also provides use of any of the aforementioned antigen-binding molecules or any of the aforementioned isolated antibodies or compositions thereof in the preparation of a medicament for treating a disease.

[0340] In another aspect, the present disclosure further provides any of the aforementioned antigen binding molecules or any of the aforementioned isolated antibodies or compositions thereof for use as a medicament. In some embodiments, the medicament is used to treat or prevent a disease.

[0341] In some embodiments, the disease as described in any of the preceding items is a proliferative disease (including tumors, cancer) or an autoimmune disease.

[0342] In some embodiments, the disease as described in any of the preceding items is a hematological malignancy or a solid tumor. In some embodiments, the hematological malignancy is multiple myeloma, relapsed / refractory multiple myeloma, smoldering multiple myeloma, monoclonal gammopathy (MGUS) (e.g., monoclonal gammopathy of undetermined significance), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma (BL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, plasma cell leukemia, light chain amyloidosis (AL), or ), precursor B-cell lymphoblastic leukemia, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), B-cell malignancies, chronic myeloid leukemia (CML), hairy cell leukemia (HCL), blastic plasmacytoid dendritic cell neoplasm, Hodgkin lymphoma, non-Hodgkin lymphoma, marginal zone B-cell lymphoma (MZBL), mucosa-associated lymphoid tissue lymphoma (MALT), plasma cell leukemia or anaplastic large cell lymphoma (ALCL). In some embodiments, the solid tumor is ovarian cancer, lung cancer (non-small cell lung cancer and small cell lung cancer), gastric cancer, prostate cancer, kidney cancer, liver cancer, colorectal cancer (such as colon cancer and rectal cancer), esophageal cancer (esophageal cancer), bladder cancer, cervical cancer or melanoma.

[0343] In some embodiments, the disease is multiple myeloma, relapsed / refractory multiple myeloma, smoldering multiple myeloma, monoclonal gammopathy (MGUS) (e.g., monoclonal gammopathy of undetermined significance), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, plasma cell leukemia, light chain amyloidosis (AL), precursor B-cell lymphoblastic leukemia, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), B-cell malignancies, chronic myeloid leukemia (CML), hairy cell leukemia (HCL), blastic plasmacytoid dendritic cell neoplasm, Hodgkin lymphoma, non-Hodgkin lymphoma, marginal zone B-cell lymphoma (MZBL), mucosa-associated lymphoid tissue lymphoma (MALT), plasma cell leukemia, anaplastic large cell lymphoma (ALCL), ovarian cancer, lung cancer, stomach cancer, prostate cancer, kidney cancer, liver cancer, colorectal cancer, esophageal cancer, bladder cancer, cervical cancer, or melanoma.

[0344] In some embodiments, the disease is multiple myeloma.

[0345] In some embodiments, the disease is relapsed / refractory multiple myeloma.

[0346] In some embodiments, the aforementioned disease is a disease associated with GPRC5D; in some embodiments, the aforementioned disease is a disease expressing GPRC5D.

[0347] The antigen-binding molecules provided by the present disclosure have the characteristics of high affinity, in vitro killing activity, therapeutic activity and safety. BRIEF DESCRIPTION OF THE DRAWINGS

[0348] FIG1A shows a schematic structural diagram of Formula 2;

[0349] FIG1B shows a schematic structural diagram of formula 2-0G4S;

[0350] FIG1C shows a schematic structural diagram of Formula 4;

[0351] FIG1D shows a schematic structural diagram of formula 4-0G4S;

[0352] FIG1E shows a schematic structural diagram of Formula 11;

[0353] Figure 2 shows the efficacy of antibody F2-1 in the NCIH929 subcutaneous xenograft tumor model. DETAILED DESCRIPTION

[0354] the term

[0355] The terms used herein are for the purpose of describing the embodiments only and are not intended to be limiting. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0356] Unless the context clearly requires otherwise, throughout the specification and claims, the words "comprising," "having," "including," and the like should be understood to have an inclusive meaning, rather than an exclusive or exhaustive meaning; that is, to mean "including but not limited to." Unless otherwise indicated, "comprising" includes "consisting of." For example, a reference to a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 specifically encompasses a GPRC5D-HCDR1 having the amino acid sequence of SEQ ID NO: 1.

[0357] The three letter and one letter codes for amino acids used in this disclosure are as described in J. biol. chem, 243, p3558 (1968).

[0358] The term "and / or," such as "X and / or Y," should be understood to mean "X and Y" or "X or Y" and should be used to provide clear support for both meanings or either meaning.

[0359] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those that are later modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids (i.e., an alpha carbon bound to a hydrogen, a carboxyl group, an amino group, and an R group), such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but function in a manner similar to naturally occurring amino acids.

[0360] The term "amino acid mutation" includes amino acid substitutions, deletions, insertions, and modifications. Any combination of substitutions, deletions, insertions, and modifications can be performed to achieve the final construct, as long as the final construct possesses the desired properties, such as reduced binding to Fc receptors. Amino acid sequence deletions and insertions include deletions and insertions at the amino and / or carboxyl termini of the polypeptide chain. A specific amino acid mutation can be an amino acid substitution. In one embodiment, the amino acid mutation is a non-conservative amino acid substitution, i.e., replacing one amino acid with another amino acid having different structural and / or chemical properties. Amino acid substitutions include replacement with non-naturally occurring amino acids or with derivatives of the 20 natural amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods known in the art. Genetic methods can include site-directed mutagenesis, PCR, gene synthesis, etc. It is expected that methods other than genetic engineering to alter amino acid side chain groups, such as chemical modification, are also useful. Various names may be used herein to refer to the same amino acid mutation. Herein, the amino acid residue at a specific position can be represented by position + amino acid residue, for example, 366W means that the amino acid residue at position 366 is W. T366W means that the amino acid residue at position 366 has mutated from T to W.

[0361] The term "antigen binding molecule" is used in the broadest sense to encompass various molecules that specifically bind to antigens, including but not limited to antibodies, other polypeptides with antigen binding activity, and antibody fusion proteins formed by fusion of the two, as long as they exhibit the desired antigen binding activity. The antigen binding molecules herein comprise a variable region (VH) and a variable region (VL), which together constitute an antigen binding domain. Exemplary, the antigen binding molecules herein are bispecific antigen binding molecules (e.g., bispecific antibodies).

[0362] The term "antibody" is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies; monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, and antibody fragments (or antigen-binding fragments, or antigen-binding portions), as long as they exhibit the desired antigen-binding activity. For example, a natural IgG antibody is a heterotetrameric glycoprotein of approximately 150,000 daltons, consisting of two identical light chains and two identical heavy chains bound by disulfide bonds. From N to C-terminus, each heavy chain has a variable region (VH), also known as a variable heavy domain, a heavy chain variable region, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N to C-terminus, each light chain has a variable region (VL), also known as a variable light domain, or a light chain variable domain, followed by a constant light domain (light chain constant region, CL).

[0363] The term "bispecific antibody" refers to an antibody (including an antibody or its antigen-binding fragment, such as a single-chain antibody) that can specifically bind to two different antigens or at least two different antigenic epitopes of the same antigen. The prior art has disclosed bispecific antibodies of various structures. Based on the integrity of the IgG molecule, they can be divided into IgG-like bispecific antibodies and antibody fragment-type bispecific antibodies. Based on the number of antigen-binding regions, they can be divided into bispecific antibodies with different valencies, such as bispecific antibodies with different valencies. Based on whether the structure is symmetrical, they can be divided into bispecific antibodies with different symmetric structures and bispecific antibodies with different asymmetric structures. Among them, bispecific antibodies based on antibody fragments, such as Fab fragments lacking Fc fragments, are formed by combining two or more Fab fragments into one molecule. They have low immunogenicity, small molecular weight, and high tumor tissue penetration. Typical antibody structures of this type include F(ab)2, scFv-Fab, and (scFv)2-Fab; IgG-like bispecific antibodies (for example, with Fc fragments) have a relatively large molecular weight. The Fc fragment helps to purify the antibody and improve its solubility and stability. The Fc part may also bind to the receptor FcRn to increase the antibody serum half-life. Typical bispecific antibody structural models include KiH, CrossMAb, Triomab quadroma, FcΔAdp, ART-Ig, BiMAb, Biclonics, BEAT, DuoBody, Azymetric, XmAb, 2:1 TCBs, and 1Fab-IgG. TDB, FynomAb, two-in-one / DAF, scFv-Fab-IgG, DART-Fc, LP-DART, CODV-Fab-TL, HLE-BiTE, F(ab)2-CrossMAb , IgG-(scFv)2, Bs4Ab, DVD-Ig, Tetravalent-DART-Fc, (scFv)4-Fc, CODV-Ig, mAb2, F(ab)4-CrossMAb, etc. (see Aran F. Labrijn et al., Nature Reviews Drug Discovery volume 18, pages 585–608 (2019); Chen S1 et al., J Immunol Res. 2019 Feb 11; 2019:4516041).

[0364] The term "variable region" or "variable domain" refers to the domain of an antigen-binding molecule that binds to an antigen. Herein, the heavy chain variable region in the antigen-binding moiety that specifically binds GPRC5D is designated as GPRC5D-VH, and the light chain variable region is designated as GPRC5D-VL; the heavy chain variable region in the antigen-binding moiety that specifically binds CD3 is designated as CD3-VH, and the light chain variable region is designated as CD3-VL. VH and VL each contain four conserved framework regions (FRs) and three complementarity-determining regions (CDRs). The term "complementarity-determining regions" or "CDRs" refers to the regions within the variable domain that primarily contribute to antigen binding; "framework" or "FRs" refers to the variable domain residues excluding the CDR residues. VH contains three CDR regions: HCDR1, HCDR2, and HCDR3; VL contains three CDR regions: LCDR1, LCDR2, and LCDR3. Herein, the three CDR regions in GPRC5D-VH are designated as GPRC5D-HCDR1, GPRC5D-HCDR2, and GPRC5D-HCDR3; the three CDR regions in GPRC5D-VL are designated as GPRC5D-LCDR1, GPRC5D-LCDR2, and GPRC5D-LCDR3; the three CDR regions in CD3-VH are designated as CD3-HCDR1, CD3-HCDR2, and CD3-HCDR3; and the three CDR regions in CD3-VL are designated as CD3-LCDR1, CD3-LCDR2, and CD3-LCDR3. From N-terminus to C-terminus, each VH and VL consists of: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. A single VH or VL may be sufficient to confer antigen-binding specificity.

[0365] The amino acid sequence boundaries of CDRs can be determined by various well-known schemes, for example: "Kabat" numbering convention (see Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD), "Chothia" numbering convention, "ABM" numbering convention, "contact" numbering convention (see Martin, ACR. Protein Sequence and Structure Analysis of Antibody Variable Domains [J]. 2001) and ImMunoGenTics (IMGT) numbering convention (Lefranc, MP et al., Dev. Comp. Immunol., 27, 55-77 (2003); Front Immunol. 2018 Oct 16; 9: 2278), etc. The correspondence between various numbering systems is well known to those skilled in the art. The numbering convention of the present disclosure is shown in Table 1 below.

[0366] Table 1. Relationships between CDR numbering systems

[0367] Unless otherwise specified, the variable region and CDR sequences in the disclosed examples are all numbered using the "Kabat" convention.

[0368] The term "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that retains the antigen-binding ability of the intact antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, single-domain antibodies, single-chain Fab (scFab), diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.

[0369] As described herein, the terms "Fab" or "Fab fragment" are used interchangeably and refer to a monovalent antibody fragment composed of VH, VL, CH1 and CL domains; herein, an antibody, such as a Fab monovalent antibody fragment of an anti-GPRC5D antibody, can be linked to the Fc1 subunit via the C-terminus of its CH1 directly or through a linker, and the formed Fab-Fc1 can be further linked to another antibody, such as Fab-Fc2 of an anti-CD3 antibody, via a disulfide bond at the N-terminus of the Fc1 subunit to form a bispecific antibody.

[0370] As used herein, the term "scFv" refers to a single-chain antibody (scFv), which is composed of the antibody heavy chain variable region (VH) and light chain variable region (VL) connected by a flexible short peptide (linker) consisting of 10-25 amino acids and is the smallest form of recombinant antibody.

[0371] The term "Fc region" or "fragment crystallizable region" is used to define the C-terminal region of the antibody heavy chain, including native Fc regions and modified Fc regions. In some embodiments, the Fc region comprises two identical or different subunits. In some embodiments, the Fc region of the human IgG heavy chain is defined as extending from the amino acid residue at the Cys226 position or from Pro230 to its carboxyl terminus. Suitable native sequence Fc regions for the antibodies described herein include human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4. Unless otherwise indicated, the numbering convention for the Fc region is the EU index.

[0372] The term "Titin chain" refers to a peptide segment of 78-118 amino acids in length containing the Titin Ig-like 152 domain or a functional variant thereof in the Titin protein, wherein the Titin chain is capable of binding to the Obscurin Ig-like 1 or Obscurin-like Ig-like 1 domain to form a dimerization complex. The term "Obscurin chain" refers to a peptide segment of 87-117 amino acids in length containing the Obscurin Ig-like 1 domain or a functional variant thereof on the Obscurin protein, or a peptide segment of 78-118 amino acids in length containing the Obscurin-like Ig-like 1 domain or a functional variant thereof on the Obscurin-like 1 protein, wherein the Obscurin chain is capable of binding to the Titin Ig-like 152 domain to form a dimerization complex. The Titin chain and the Obscurin chain disclosed herein can be used to replace the CH1 and CL in Fab to form a replaced Fab (Fab-S), and this replacement does not affect the binding of the antigen-binding molecule to the antigen.

[0373] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0374] The term "humanized" antibody is an antibody that retains the reactivity of a non-human antibody while having lower immunogenicity in humans. For example, this can be achieved by retaining the non-human CDR regions and replacing the rest of the antibody with their human counterparts (i.e., the constant region and the framework region portion of the variable region).

[0375] The term "affinity" refers to the overall intensity of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to internal binding affinity, which reflects 1:1 interactions between members of a binding pair (e.g., an antibody and an antigen). The affinity of molecule X to its part Y can generally be represented by an equilibrium dissociation constant (KD). Affinity can be measured by conventional methods known in the art (including those described herein). The terms "kassoc" or "ka" refer to the on-rate of a specific antibody-antigen interaction, and the terms "kdis" or "kd" as used herein are intended to refer to the off-rate of a specific antibody-antigen interaction. As used herein, the term "KD" refers to an equilibrium dissociation constant, which is derived from the ratio of kd to ka (i.e., kd / ka) and is expressed as molar concentration (M). The KD value of an antibody can be measured using methods known in the art, such as surface plasmon resonance, ELISA, or solution equilibrium titration (SET).

[0376] The term "monoclonal antibody" refers to a group of substantially homogeneous antibodies, i.e., the amino acid sequences of the antibody molecules contained in the group are identical, except for the natural mutations that may be present in small amounts. In contrast, polyclonal antibody preparations are typically comprised of a variety of different antibodies with different amino acid sequences in their variable domains, which are typically specific for different epitopes. "Monoclonal" represents the characteristic of an antibody obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring the production of an antibody by any ad hoc method. In some embodiments, the antibody provided by the present disclosure is a monoclonal antibody.

[0377] The term "antigen" refers to a molecule or portion of a molecule that can be bound by a selective binding agent of an antigen binding protein (eg, an antibody). An antigen may have one or more epitopes that can interact with different antigen binding proteins (eg, antibodies).

[0378] The term "epitope" refers to an area or region on an antigen that is capable of specific binding to an antibody or its antigen-binding fragment. An epitope can be formed by contiguous amino acids (linear epitope) or comprise non-contiguous amino acids (conformational epitope), for example, when the non-contiguous amino acids are brought into spatial proximity due to the folding of the antigen (i.e., by the tertiary folding of the antigen in the case of proteinaceous properties). Conformational epitopes differ from linear epitopes in that antibody binding to the conformational epitope is lost in the presence of denaturing solvents. An epitope comprises at least 3, at least 4, at least 5, at least 6, at least 7, or 8-10 amino acids in a unique spatial conformation. Screening for antibodies that bind to a particular epitope (i.e., those that bind to the same epitope) can be performed using routine methods in the art, such as, but not limited to, alanine scanning, peptide blotting (see Meth. Mol. Biol. 248 (2004) 443-463), peptide cleavage analysis, epitope excision, epitope extraction, chemical modification of antigens (see Prot. Sci. 9 (2000) 487-496), and cross-blocking (see "Antibodies", Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harb., NY)).

[0379] The terms "capable of specifically binding", "specific binding" or "binding" refer to the ability of an antibody to bind to an antigen or epitope with a higher affinity than to other antigens or epitopes. -7 M or less (e.g., about 1×10 -8 In some embodiments, the antibody binds to the antigen with an equilibrium dissociation constant (KD) of 5,4,5-M or less. In some embodiments, the antibody binds to the antigen with a KD that is 10% or less (e.g., 1%) of the KD of the antibody bound to a nonspecific antigen (e.g., BSA, casein). KD can be measured using known methods, such as those measured by FACS or surface plasmon resonance assays. However, an antibody that specifically binds to an antigen or an epitope within an antigen may have cross-reactivity to other related antigens, for example, to corresponding antigens from other species (homologous) such as humans or monkeys, e.g., Macaca fascicularis (cynomolgus, cyno), Pan troglodytes (chimpanzee, chimp), or Callithrix jacchus (common marmoset, marmoset).

[0380] The term "no binding" means that the antibody is unable to bind to an antigen or an epitope within the antigen in the manner described above. For example, when the antibody is about 1×10 -6The antigen binds to an antigen or an epitope within an antigen with an equilibrium dissociation constant (KD) of M or greater.

[0381] The term "antigen binding moiety" refers to a polypeptide molecule that specifically binds to a target antigen. Specific antigen binding moieties include the antigen binding domain of an antibody, for example, comprising a heavy chain variable region and a light chain variable region. The term "antigen binding moiety that specifically binds to GPRC5D" refers to a module that can bind to GPRC5D with sufficient affinity so that a molecule containing the module can be used as a diagnostic and / or therapeutic agent targeting GPRC5D. For example, an antigen binding moiety that specifically binds to GPRC5D has the following equilibrium dissociation constant (KD): <about 10 nM, which is measured by surface plasmon resonance assay. Antigen binding moieties include antibody fragments as defined herein, such as Fab, substituted Fab or scFv.

[0382] The term "linker" refers to a connecting unit that connects two polypeptide fragments. As used herein, linkers appearing in the same structural formula may be the same or different. A linker may be a peptide linker comprising one or more amino acids, typically about 1-30, 2-24, or 3-15 amino acids. The linkers used herein may be the same or different. When "-" appears in a structural formula, it indicates that the units on either side are directly connected by a covalent bond.

[0383] "Tm" is the melting denaturation temperature (intrinsic fluorescence). When a protein denatures (by heat or denaturants), the tertiary structure opens up, the microenvironment of the aromatic amino acids changes, and the emitted fluorescence spectrum shifts. For purposes of this disclosure, Tm1 refers to the temperature at which fluorescence reaches half its maximum value.

[0384] "Tonset" is the denaturation onset temperature. It refers to the temperature at which the protein begins to denature, that is, the temperature at which the fluorescence value begins to change.

[0385] "Tagg" stands for aggregation onset temperature. Aggregates are detected by static light scattering at two wavelengths, 266 nm and 473 nm, to measure the temperature at which the sample begins to aggregate. Tagg 266 refers to the aggregation onset temperature measured at 266 nm.

[0386] The term "nucleic acid" is used interchangeably with the term "polynucleotide" in this article, and refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single-stranded or double-stranded form. The term encompasses backbone residues or connected nucleic acids containing known nucleotide analogs or modifications, which are synthetic, naturally occurring, and non-naturally occurring, with binding properties similar to reference nucleic acids, and metabolized in a manner similar to reference nucleotides. The example of such analogs includes, but is not limited to, phosphorothioate, phosphoramidate, methylphosphonate, chiral-methylphosphonate, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs). "Isolated" nucleic acid refers to a nucleic acid molecule separated from the component of its natural environment. Isolation nucleic acid is included in the nucleic acid molecule contained in the following cells, which cells typically contain the nucleic acid molecule, but the nucleic acid molecule is present in extrachromosomal or in a chromosomal position different from its natural chromosomal position. The nucleic acid encoding the separation of the antigen binding molecules refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or its fragment), including such one or more nucleic acid molecules in a single vector or a separate vector, and such one or more nucleic acid molecules present in one or more positions in a host cell. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as explicitly indicated sequences. Specifically, as described in detail below, degenerate codon substitutions can be obtained by generating sequences in which the third position of one or more selected (or all) codons is substituted with a degenerate base and / or deoxyinosine residue.

[0387] The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The term applies to amino acid polymers in which one or more amino acid residues is an artificial chemical mimetic of a naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. Unless otherwise indicated, a particular polypeptide sequence also implicitly encompasses conservatively modified variants thereof.

[0388] The term sequence "identity" refers to the degree (percentage) at which the amino acid / nucleic acid of the two sequences are identical in the equivalent position when two sequences are optimally aligned. In the alignment process, it may be allowed, if necessary, to introduce a gap to obtain maximum sequence identity percentage, but any conservative substitution is not considered to constitute a part for sequence identity. For measuring sequence identity percentage, alignment can be achieved by techniques known in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine the parameters applicable to measuring alignment, including any algorithm required for maximum alignment, which is included in the full length of the sequence being compared.

[0389] The term "fused" or "linked" means that the components (eg, an antigen binding moiety and an Fc domain) are covalently linked directly or via a linker.

[0390] The term "vector" means a polynucleotide molecule capable of transporting another polynucleotide connected thereto. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop, wherein additional DNA segments can be connected. Another type of vector is a viral vector, such as an adeno-associated viral vector (AAV or AAV2), in which additional DNA segments can be connected to the viral genome. Certain vectors can replicate autonomously in the host cell in which they are introduced (for example, bacterial vectors and additional mammalian vectors with bacterial replication origins). Other vectors (for example, non-additional mammalian vectors) can be integrated into the genome of the host cell after being introduced into the host cell, thereby replicating together with the host genome. The term "expression vector" or "expression construct" refers to a vector suitable for transforming a host cell and containing a nucleic acid sequence for guiding and / or controlling (together with the host cell) the expression of one or more heterologous coding regions operably connected thereto. An expression construct can include but is not limited to affecting or controlling transcription, translation and affecting the sequence of RNA splicing of the coding region operably connected thereto when introns are present.

[0391] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived therefrom, without regard to the number of passages. Progeny may not be completely identical to the parent cell in nucleic acid content, but may contain mutations. As used herein, the term includes mutant progeny that have the same function or biological activity as the cell screened or selected in the primary transformed cell. Host cells include prokaryotic and eukaryotic host cells, wherein eukaryotic host cells include, but are not limited to, mammalian cells, insect cell lines, plant cells, and fungal cells. Mammalian host cells include human, mouse, rat, dog, monkey, pig, goat, cow, horse, and hamster cells, including but not limited to Chinese hamster ovary (CHO) cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, and HEK-293 cells.Fungal cells include yeast and filamentous fungal cells, including, for example, Pichia pastoris, Pichia finlandica, Pichia trehalophila, Pichia koclamae, Pichia membranaefaciens, Pichia minuta (Ogataea minuta, Pichia lindneri), Pichia truncatula, Pichia thermotolerans, Pichia salictaria, Pichia guercuum, Pichia pijperi, Pichia stiptis, Pichia methanolica, Pichia sp., Saccharomyces cerevisiae, Saccharomyces cerevisiae, Hansenula polymorpha, polymorpha), Kluyveromyces spp., Kluyveromyces lactis, Candida albicans, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Trichoderma reesei, Chrysosporium lucknowense, Fusarium sp., Fusarium gramineum, Fusarium venenatum, Physcomitrella patens, and Neurospora crassa. Pichia, any Saccharomyces, Hansenula polymorpha, any Kluyveromyces, Candida albicans, any Aspergillus, Trichoderma reesei, Chrysosporium lucknowense, any Fusarium, Yarrowia lipolytica, and Neurospora crassa. The host cells of this patent do not include subject matter not authorized under patent law.

[0392] As used in this application, the expressions "cell," "cell line," and "cell culture" are used interchangeably, and all such designations include progeny. Thus, the terms "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom, regardless of the number of passages. It is also understood that not all progeny have exactly the same DNA content, due to intentional or unintentional mutations. Mutant progeny that have the same function or biological activity as the original transformed cell from which they were selected are included.

[0393] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0394] The term "pharmaceutical composition" refers to a mixture containing one or more antigen binding molecules or antibodies described herein with other chemical components, such as physiologically / pharmaceutically acceptable carriers and excipients.

[0395] The term "pharmaceutically acceptable carrier" refers to a component of a pharmaceutical formulation that is different from the active ingredient and is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0396] The term "subject" or "individual" includes humans and non-human animals. Non-human animals include all vertebrates (e.g., mammals and non-mammals) such as non-human primates (e.g., cynomolgus monkeys), sheep, dogs, cows, chickens, amphibians, and reptiles. Unless explicitly stated, the terms "patient" or "subject" are used interchangeably herein. As used herein, the term "cynomolgus monkey" or "cynomolgus monkey" refers to cynomolgus monkeys (Macaca fascicularis). In certain embodiments, the individual or subject is a human.

[0397] "Administering" or "administering," as it applies to an animal, human, experimental subject, cell, tissue, organ or biological fluid, refers to the contact of an exogenous drug, therapeutic agent, diagnostic agent or composition with the animal, human, subject, cell, tissue, organ or biological fluid.

[0398] The term "sample" refers to a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present in a subject. Exemplary samples are biological fluids such as blood, serum and serosal fluid, plasma, lymph, urine, saliva, cystic fluid, tears, feces, sputum, mucosal secretions of secretory tissues and organs, vaginal secretions, ascites, pleura, pericardium, peritoneum, fluids of the abdominal cavity and other body cavities, fluids collected by bronchial lavage, synovial fluid, liquid solutions in contact with a subject or biological source, such as cell and organ culture media (including cell or organ conditioned media), lavage fluids, etc., tissue biopsy samples, fine needle aspirations, surgically resected tissues, organ cultures, or cell cultures.

[0399] "Treatment" and "treatment" (and grammatical variations thereof) refer to a clinical intervention attempted to be applied to the individual being treated, and can be performed for preventive purposes or during the course of clinical pathology. The desired effects of treatment include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, alleviating / reducing any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, improving or alleviating the disease state, and remission or improved prognosis. In some embodiments, the molecules of the present disclosure are used to delay the development of the disease or slow the progression of the disease.

[0400] "Effective amount" is generally enough to reduce the severity and / or frequency of symptoms, eliminate these symptoms and / or potential causes, prevent symptoms and / or their potential causes from occurring and / or improve or ameliorate the damage (e.g., lung disease) caused by or associated with the disease state. In some embodiments, an effective amount is a therapeutically effective amount or a prophylactic effective amount. A "therapeutically effective amount" is enough to treat a disease state or symptom, particularly a state or symptom associated with the disease state, or otherwise prevent, hinder, delay or reverse the disease state or any other undesirable symptom associated with the disease in any way. A "prophylactic effective amount" is an amount that will have a predetermined preventive effect when administered to a subject, such as preventing or delaying the onset (or recurrence) of the disease state, or reducing the likelihood of the onset (or recurrence) of the disease state or associated symptoms. A complete treatment or prophylactic effect may not occur after administering one dose, but may occur after administering a series of doses. Thus, a therapeutically or prophylactically effective amount can be administered in one or more doses. A "therapeutically effective amount" and a "prophylactically effective amount" can vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the therapeutic agent or combination of therapeutic agents to elicit a desired response in the individual. Exemplary indicators of an effective therapeutic agent or combination of therapeutic agents include, for example, improved health status of the patient.

[0401] Antigen-binding molecules of the present disclosure

[0402] The present disclosure provides antigen-binding molecules that have a number of advantageous properties, such as high affinity for GPRC5D and cells expressing GPRC5D, in vitro killing activity, therapeutic activity, and safety.

[0403] Exemplary Antigen Binding Molecules

[0404] The antigen-binding molecules disclosed herein include bispecific antigen-binding molecules (e.g., bispecific antibodies) and anti-GPRC5D antibodies that specifically bind to GPRC5D and CD3. In particular, the antigen-binding molecules disclosed herein have any of the following properties:

[0405] a. High affinity for GPRC5D; in some embodiments, with an EC less than 50 nM (e.g., less than 25 nM, less than 20 nM, less than 15 nM, less than 10 nM, less than 5 nM, less than 2.5 nM, less than 1 nM, less than 0.5 nM) 50 Binds to human GPRC5D and / or binds to human GPRC5D with an EC less than 50 nM (e.g., less than 25 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM). 50 It has good cross-binding activity with CynoGPRC5D. 50 It was detected by flow cytometry;

[0406] b. Does not bind to human CCR8 and human GIPR, and has good specificity;

[0407] c. In vitro specific killing activity against cells expressing GPRC5D;

[0408] d. Inducing low levels of cytokine (IL6 and IFNγ) release; and / or

[0409] e. Greater in vivo therapeutic activity.

[0410] The present disclosure provides an antigen binding molecule comprising at least one antigen binding moiety that specifically binds to GPRC5D and at least one antigen binding moiety that specifically binds to CD3, wherein the antigen binding moiety that specifically binds to GPRC5D comprises GPRC5D-VH and GPRC5D-VL, and the antigen binding moiety that specifically binds to CD3 comprises CD3-VH and CD3-VL.

[0411] The present disclosure also provides an isolated antibody that can specifically bind to GPRC5D, wherein the antibody comprises GPRC5D-VH and GPRC5D-VL. Specifically, the embodiments herein disclose antibody series 1, 24, 30, and 45. The antibodies herein are described below using antibodies 1 and 24 as examples.

[0412] An antigen-binding molecule or anti-GPRC5D antibody that specifically binds to GPRC5D and CD3, wherein the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14.

[0413] An antigen-binding molecule or anti-GPRC5D antibody that specifically binds to GPRC5D and CD3, wherein the GPRC5D-VH has: a GPRC5D-HCDR1 as shown in SEQ ID NO: 9, a GPRC5D-HCDR2 as shown in SEQ ID NO: 134, a GPRC5D-HCDR3 as shown in SEQ ID NO: 11, and a GPRC5D-LCDR1 as shown in SEQ ID NO: 130, a GPRC5D-LCDR2 as shown in SEQ ID NO: 13, and a GPRC5D-LCDR3 as shown in SEQ ID NO: 14.

[0414] An antigen-binding molecule or anti-GPRC5D antibody that specifically binds to GPRC5D and CD3, wherein the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 137, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20.

[0415] An antigen-binding molecule or anti-GPRC5D antibody that specifically binds to GPRC5D and CD3, wherein the GPRC5D-VH has: a GPRC5D-HCDR1 as shown in SEQ ID NO: 15, a GPRC5D-HCDR2 as shown in SEQ ID NO: 16, a GPRC5D-HCDR3 as shown in SEQ ID NO: 17, and a GPRC5D-LCDR1 as shown in SEQ ID NO: 137, a GPRC5D-LCDR2 as shown in SEQ ID NO: 19, and a GPRC5D-LCDR3 as shown in SEQ ID NO: 20.

[0416] In some embodiments, the antigen binding molecule or antibody as described above, the GPRC5D-VH and / or the GPRC5D-VL are murine or humanized.

[0417] In some embodiments, the GPRC5D-VH and / or the GPRC5D-VL are humanized.

[0418] In some embodiments, the GPRC5D-VH comprises FR1, FR2, FR3 derived from IGHV3-21*01 and FR4 derived from IGHJ6*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 49A and 93T; and / or the GPRC5D-VL comprises FR1, FR2, FR3 derived from IGKV2-29*02 and FR4 derived from IGKJ2*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 2V and 45K. In some embodiments, the variable regions and CDRs are defined according to the Kabat numbering convention.

[0419] In some embodiments, the antigen binding molecule or antibody of any of the preceding items, wherein the amino acid sequence of the GPRC5D-VH has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 35, 1, 33 or 34, and the amino acid sequence of the GPRC5D-VL has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 39, 2, 36, 37, 38, 40 or 41.

[0420] In some embodiments, the GPRC5D-VH and / or the GPRC5D-VL are humanized.

[0421] In some embodiments, the GPRC5D-VH comprises FR1, FR2, FR3 derived from IGHV1-46*01 and FR4 derived from IGHJ6*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1E, 24V, 37M, 69W, 71A, 73K, and 93S; and / or the GPRC5D-VL comprises FR1, FR2, FR3 derived from IGKV2-30*02 and FR4 derived from IGKJ4*01, and is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 4L, 28T, 28S, 29L, 29V, 36L, and 37L. In some embodiments, the variable regions and CDRs are defined according to the Kabat numbering convention.

[0422] In some embodiments, the antigen binding molecule or antibody of any of the preceding items, wherein the amino acid sequence of the GPRC5D-VH has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 44, 3, 42 or 43, and the amino acid sequence of the GPRC5D-VL has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 49, 4, 45, 46, 47, 48 or 50.

[0423] In some embodiments, the amino acid sequence of the GPRC5D-VH is shown in SEQ ID NO: 35, 1, 33 or 34, and the amino acid sequence of the GPRC5D-VL is shown in SEQ ID NO: 39, 2, 36, 37, 38, 40 or 41.

[0424] In some embodiments, the amino acid sequence of the GPRC5D-VH is shown in SEQ ID NO: 35, 33 or 34, and the amino acid sequence of the GPRC5D-VL is shown in SEQ ID NO: 39, 36, 37, 38, 40 or 41.

[0425] In some embodiments, the amino acid sequence of the GPRC5D-VH is shown in SEQ ID NO: 44, 3, 42 or 43, and the amino acid sequence of the GPRC5D-VL is shown in SEQ ID NO: 49, 4, 45, 46, 47, 48 or 50.

[0426] In some embodiments, the amino acid sequence of the GPRC5D-VH is shown in SEQ ID NO: 44, 42 or 43, and the amino acid sequence of the GPRC5D-VL is shown in SEQ ID NO: 49, 45, 46, 47, 48 or 50.

[0427] In some embodiments, the antigen binding molecule or antibody as described in any of the preceding items, wherein

[0428] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39; or

[0429] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 36; or

[0430] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 38; or

[0431] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39; or

[0432] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 36; or

[0433] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 38; or

[0434] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 1, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 2.

[0435] In some embodiments, the antigen binding molecule or antibody of any of the preceding items, wherein the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39.

[0436] In some embodiments, the antigen binding molecule or antibody of any of the preceding items, wherein the amino acid sequence of the GPRC5D-VH is as shown in SEQ ID NO: 35, and the amino acid sequence of the GPRC5D-VL comprises as shown in SEQ ID NO: 39.

[0437] In some embodiments, the antigen binding molecule or antibody as described in any of the preceding items, wherein

[0438] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or

[0439] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 46; or

[0440] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or

[0441] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 50; or

[0442] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 46; or

[0443] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 50; or

[0444] The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 3, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 4.

[0445] In some embodiments, the antigen binding molecule or antibody of any of the preceding items, wherein the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49.

[0446] In some embodiments, the antigen binding molecule or antibody of any of the preceding items, wherein the amino acid sequence of the GPRC5D-VH is as shown in SEQ ID NO: 44, and the amino acid sequence of the GPRC5D-VL comprises as shown in SEQ ID NO: 49.

[0447] In some embodiments, in the antigen binding molecule as described above, the CD3-VH has: CD3-HCDR1 with an amino acid sequence as shown in SEQ ID NO: 76, CD3-HCDR2 with an amino acid sequence as shown in SEQ ID NO: 77, and CD3-HCDR3 with an amino acid sequence as shown in SEQ ID NO: 78; and the CD3-VL has: CD3-LCDR1 with an amino acid sequence as shown in SEQ ID NO: 79, CD3-LCDR2 with an amino acid sequence as shown in SEQ ID NO: 80, and CD3-LCDR3 with an amino acid sequence as shown in SEQ ID NO: 81.

[0448] In some embodiments, according to any of the preceding antigen binding molecules, the CD3-VH and / or the CD3-VL are murine or humanized.

[0449] In some embodiments, the CD3-VH and / or the CD3-VL are humanized.

[0450] In some embodiments, the amino acid sequence of the CD3-VH is shown in SEQ ID NO:82, and the amino acid sequence of the CD3-VL is shown in SEQ ID NO:83.

[0451] In some embodiments, the variable regions and CDRs described above are defined according to the Kabat numbering convention.

[0452] According to the technical solutions of antibody series 30 and 45 disclosed in the Examples herein, these antibodies have a similar technical solution scope to antibodies 1 and 24 described above.

[0453] Structure of antigen-binding molecules

[0454] The bispecific antigen binding molecules disclosed herein are not limited to specific molecular structures, as long as they have desired antigen binding function. For example, the bispecific antigen binding molecules herein can be divalent (1+1), trivalent (2+1) or quadrivalent (2+2). The antigen binding module in the antigen binding molecules can be any antibody fragment with antigen binding activity, which is fused by a peptide connexon. The peptide connexons (such as connexons 1 to 6) disclosed herein can be any suitable peptide chain, as long as the antigen binding molecules can show desired antigen binding activity. For example, the peptide connexons can be flexible peptides of 1-50 or 3-20 amino acid residues. In some embodiments, the peptide linkers each independently have a structure of L1-(GGGGS)n-L2, wherein L1 is a bond, A, GS, GGS, GGGS (SEQ ID NO: 213), n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, L2 is a bond, G, GG, GGG (SEQ ID NO: 95) or GGGG (SEQ ID NO: 214), and the peptide linker is not a bond. In some embodiments, the peptide linker is 3-15 amino acid residues in length. In some embodiments, the peptide linkers each independently comprise an amino acid sequence of (GGGGS)n, wherein n is 1-5; preferably, n is 1, 2 or 3. In some embodiments, the peptide linker is GGGGS (SEQ ID NO: 90), GGGGSGGGGSGGGGS (SEQ ID NO: 94) or GGG (SEQ ID NO: 95). In some embodiments, the amino acid sequences of linker 1, linker 2, linker 3, and linker 4 are shown in SEQ ID NO: 90; the amino acid sequence of linker 5 is shown in SEQ ID NO: 94; and the amino acid sequence of linker 6 is shown in SEQ ID NO: 95.

[0455] Exemplarily, the antigen-binding molecule disclosed herein comprises a first chain having a structure as shown in formula (i), a second chain having a structure as shown in formula (j), a third chain having a structure as shown in formula (k-1), and a fourth chain having a structure as shown in formula (l-1).

[0456] (a) [GPRC5D-VH]-[CH1]-[Fc1],

[0457] (b) [GPRC5D-VL]-CL,

[0458] (g-1)[CD3-VH]-[GGGGS]-[Obscurin chain]-[Fc2],

[0459] (h-1) [CD3-VL]-[GGGGS]-[Titin chain],

[0460] The structures represented by formulae (a), (b), (g-1) and (h-1) are arranged from the N-terminus to the C-terminus.

[0461] Exemplary:

[0462] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 118, a second chain comprising the amino acid sequence of SEQ ID NO: 102, a third chain comprising the amino acid sequence of SEQ ID NO: 84, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 85; or

[0463] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 120, a second chain comprising the amino acid sequence of SEQ ID NO: 106, a third chain comprising the amino acid sequence of SEQ ID NO: 84, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 85; or

[0464] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 122, a second chain comprising the amino acid sequence of SEQ ID NO: 110, a third chain comprising the amino acid sequence of SEQ ID NO: 84, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 85; or

[0465] The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 124, a second chain comprising the amino acid sequence of SEQ ID NO: 117, a third chain comprising the amino acid sequence of SEQ ID NO: 84, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 85.

[0466] Variants of antigen-binding molecules

[0467] In certain embodiments, the amino acid sequence variants of the antigen binding molecules provided herein are encompassed.For example, it is desirable to improve the binding affinity and / or other biological properties of the antibody. Suitable modifications can be introduced into the nucleotide sequence encoding the antibody, or the amino acid sequence variants of the antibody can be prepared by peptide synthesis. Such modifications include, for example, deletion and / or insertion and / or replacement of the residues in the amino acid sequence of the antigen binding molecules. Any combination of deletion, insertion and replacement can be performed to obtain final construct, as long as final construct has desired features, for example, antigen binding properties.

[0468] Substitution, insertion, and deletion variants

[0469] In certain embodiments, antigen binding molecule variants with one or more amino acid substitutions are provided. Substitutions can be made in CDR and FR. Conservative substitutions are shown under the heading of "preferred substitutions" in Table 2. More substantial variations are provided under the heading of "illustrative substitutions" in Table 2, and are further described below with reference to amino acid side chain classes. Amino acid substitutions can be introduced into the antibody of interest, and the desired activity of the product screening is determined, such as the antigen binding to which retention / improvement is sought, the immunogenicity to which reduction is sought, or the ADCC or CDC to which improvement is sought.

[0470] Table 2. Amino acid substitutions

[0471] Based on common side chain properties, amino acids can be grouped as follows:

[0472] (1) Hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;

[0473] (2) Neutral, hydrophilic: Cys, Ser, Thr, Asn, Gln;

[0474] (3) Acidic: Asp, Glu;

[0475] (4) Basic: His, Lys, Arg;

[0476] (5) Residues that affect chain orientation: Gly, Pro;

[0477] (6) Aromatic: Trp, Tyr, Phe.

[0478] Non-conservative substitutions would involve exchanging a member from one class for a member from another class.

[0479] A class of substitution variants involves replacing one or more CDR residues of a parent antibody (e.g., humanized or human antibody). Generally, the variants selected for further study will have changes (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody, and / or will substantially retain certain biological properties of the parent antibody. An exemplary substitution variant is an affinity-matured antibody, which can be readily produced using, for example, affinity maturation techniques based on phage display (e.g., those described herein). In short, one or more CDR residues are mutated, and the variant antibody is displayed on phage, and screened for specific biological activity (e.g., binding affinity). Changes (e.g., substitutions) can be made to CDR, for example, to improve antibody affinity. Such changes can be made to CDR "hot spots," i.e., residues encoded by codons that undergo mutations at high frequency during the somatic maturation process, and / or residues contacting antigens, while binding affinity is tested for the variant VH or VL obtained. In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., fallibility PCR, chain shuffling, or oligonucleotide-guided mutagenesis). Then, a secondary library is created. The library is then screened to identify any antibody variant with desired affinity. Another method of introducing diversity relates to a CDR-directed method in which several CDR residues (e.g., 4-6 residues at a time) are randomized. CDR residues that specifically identify antigen binding can be, for example, identified using alanine scanning mutagenesis or modeling.

[0480] In certain embodiments, substitutions, insertions, or deletions may occur within one or more CDRs, as long as such changes do not substantially reduce the ability of the antibody to bind to antigen. For example, conservative changes (e.g., conservative substitutions, as provided herein) may be made to the CDRs that do not substantially reduce binding affinity. In certain embodiments of the variant VH and VL sequences provided above, each CDR is unchanged or contains no more than 1, 2, or 3 amino acid substitutions.

[0481] A method that can be used to identify residues or regions that can be used as mutagenesis targets in antibodies is called "alanine scanning mutagenesis". In this method, a residue or residue group (e.g., charged residues, such as Arg, Asp, His, Lys, and Glu) is identified and replaced with neutral or negatively charged amino acids (e.g., Ala or polyalanine) to determine whether the interaction between the antibody and the antigen is affected. Further substitutions can be introduced at amino acid positions that show functional sensitivity to the initial substitution. In addition, the contact points between the antibody and the antigen can be identified by studying the crystal structure of the antigen-antibody complex. These contact residues and adjacent residues can be targeted or eliminated as substitution candidates. Variants can be screened to determine whether they contain desired properties.

[0482] Amino acid sequence insertions include: fusions of one residue or polypeptides of 100 or more residues in length to the amino and / or carboxyl termini; and intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies with an N-terminal methionyl residue. Other insertional variants of antibody molecules include fusions of enzymes (or polypeptides that extend the serum half-life of the antibody) to the N- or C-termini of the antibody.

[0483] Fab Transformation

[0484] In one aspect, in the antigen binding molecules disclosed herein, one of the antigen binding moiety that specifically binds to GPRC5D and the antigen binding moiety that specifically binds to CD3 is a replaced Fab, and the replaced Fab comprises a heavy chain variable region, a light chain variable region, a titin chain, and an obscurin chain. In the replaced Fab, the original CH1 and CL of the Fab are replaced by the titin chain and the obscurin chain (for example, the original CH1 and CL of the Fab are replaced by the obscurin chain and the titin chain, respectively, or the original CH1 and CL of the Fab are replaced by the titin chain and the obscurin chain, respectively). Exemplary, the sequences of the titin chain and the obscurin chain are shown in Tables 3-1 and 3-2.

[0485] Table 3-1. Amino acid sequence of titin chain

[0486] Table 3-2. Amino acid sequence of obscurin chain

[0487] Renovation of the Fc region

[0488] In one aspect, the Fc region of the antigen-binding molecule of the present disclosure comprises one or more amino acid substitutions that reduce its binding to an Fc receptor, such as its binding to an Fcγ receptor, and reduce or eliminate effector function. A native IgG Fc region, specifically an IgG1 Fc region or an IgG4 Fc region, may cause the antigen-binding molecule of the present disclosure to target cells expressing Fc receptors rather than cells expressing antigens. The modified Fc region of the present disclosure exhibits reduced binding affinity to Fc receptors and / or reduced effector function. In some embodiments, the modified Fc region has a binding affinity to Fc receptors that is reduced by 50%, 80%, 90% or more than 95% compared to the native Fc region. In some embodiments, the Fc receptor is an Fcγ receptor. In some embodiments, the Fc receptor is a human Fcγ receptor, such as FcγRI, FcγRIIa, FcγRIIB, or FcγRIIIa. In some embodiments, the Fc region of the transformation has a reduced binding affinity for complement, such as C1q, compared to the native Fc region. In some embodiments, the Fc region of the transformation has a reduced binding affinity for neonatal Fc receptor (FcRn) compared to the native Fc region. In some embodiments, the Fc region of the transformation has reduced effector functions, which can include but are not limited to one or more of the following: reduced complement dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen-presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling-induced apoptosis, reduced dendritic cell maturation, or reduced T cell priming. For the IgG1 Fc region, substitutions of amino acid residues at positions 238, 265, 269, 270, 297, 327, and 329 can reduce effector function. In some embodiments, the Fc region is a human IgG1 Fc region, and the amino acid residues at positions 234 and 235 are A, numbering according to the EU index. For the IgG4 Fc region, substitutions of amino acid residues at positions 228, etc. can reduce effector function.

[0489] The antigen-binding molecule may further comprise disulfide bond modifications, such as 354C in the first subunit and 349C in the second subunit. To increase the serum half-life of the antigen-binding molecule, mutations 252Y, 254T, and 256E may be introduced.

[0490] When the antigen binding molecules include different binding modules fused to the two subunits in the Fc region, undesirable homodimerization may result. In order to improve yield and purity, it is therefore advantageous to introduce a modification that promotes heterodimerization in the Fc region of the antigen binding molecules of the present disclosure. In some embodiments, the Fc region of the present disclosure includes the transformation according to knob-into-hole (KIH) technology, which involves introducing a protrusion structure (knob) at the interface of the first subunit and introducing a hole structure (hole) at the interface of the second subunit. The protrusion structure is positioned in the hole structure, promoting the formation of heterodimers and suppressing the generation of homodimers. The protrusion structure is constructed by replacing the small amino acid side chains from the interface of the first subunit with larger side chains (such as tyrosine or tryptophan). The hole structure is created in the interface of the second subunit by replacing large amino acid side chains with smaller amino acid side chains (such as alanine or threonine). Protrusion structure and hole structure are prepared by changing the nucleic acid encoding the polypeptide, and optional amino acid substitutions are shown in the table below:

[0491] Table 4. KIH mutation combinations

[0492] In addition to the knob-in-hole technique, other techniques for modifying the CH3 domain of the heavy chain to achieve heterodimerization are also known in the art, such as WO96 / 27011, WO98 / 050431, EP1870459, WO2007 / 110205, WO2007 / 147901, WO2009 / 089004, WO2010 / 129304, WO2011 / 90754, WO2011 / 143545, WO2012 / 058768, WO2013 / 157954 and WO013 / 096291.

[0493] The C-terminus of the Fc region can be a complete C-terminus ending with the amino acid residue PGK; or it can be a truncated C-terminus, for example, in which one or two C-terminal amino acid residues are removed. In a preferred aspect, the C-terminus of the heavy chain is a shortened C-terminus ending with PG. Therefore, in some embodiments, a composition of intact antibodies can include a population of antibodies in which all K447 residues and / or G446+K447 residues have been removed. In some embodiments, a composition of intact antibodies can include a population of antibodies in which the K447 residue and / or G446+K447 residues have not been removed. In some embodiments, a composition of intact antibodies has a population of antibodies that are a mixture of antibodies with and without the K447 residue and / or G446+K447 residues.

[0494] Recombination methods

[0495] Antigen binding molecules can be produced using recombinant methods.For these methods, one or more isolated nucleic acids encoding the antigen binding molecules are provided.

[0496] In the case of a natural antibody, a natural antibody fragment or a bispecific antibody with a homodimer heavy chain, two nucleic acids are required, one for a light chain or its fragment and one for a heavy chain or its fragment. Such nucleic acid encoding comprises the amino acid sequence of antibody VL and / or comprises the amino acid sequence of antibody VH (e.g., light chain and / or heavy chain of an antibody). These nucleic acids can be on the same expression vector or on different expression vectors.

[0497] In the case of a bispecific antibody with a heterodimeric heavy chain, for example, four nucleic acids are required: one for the first light chain, one for the first heavy chain comprising a first heterologous monomeric Fc region polypeptide, one for the second light chain, and one for the second heavy chain comprising a second heterologous monomeric Fc region polypeptide. These four nucleic acids can be contained in one or more nucleic acid molecules or expression vectors, typically these nucleic acids are located on two or three expression vectors, i.e., one vector can contain more than one of these nucleic acids.

[0498] In one embodiment, present disclosure provides the nucleic acid encoding the separation of an antibody as described above. Such nucleic acid can independently encode any of the aforementioned polypeptide chains. On the other hand, present disclosure provides one or more vectors (such as expression vectors) comprising such nucleic acid. On the other hand, present disclosure provides a host cell comprising such nucleic acid. In one embodiment, there is provided a method for preparing an antigen binding molecule, wherein the method comprises, under conditions suitable for antibody expression, cultivating a host cell comprising the nucleic acid encoding the antibody, as provided above, and optionally reclaiming the antibody from a host cell (or host cell culture medium).

[0499] In order to recombinantly produce antigen binding molecules, the nucleic acid of coded protein is separated and inserted into one or more vectors, for further cloning and / or expressing in host cell.Such nucleic acid can be easily separated and sequenced (for example, by using oligonucleotide probes that can be combined with the gene specificity of encoding antibody heavy chain and light chain) using conventional procedures, or produced by recombinant method or obtained by chemical synthesis.

[0500] Suitable host cells for cloning or expressing antibody-encoding vectors include the prokaryotic or eukaryotic cells described herein. For example, antibodies can be produced in bacteria, particularly when glycosylation and Fc effector functions are not required for the antibodies. Following expression, the antibodies can be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

[0501] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are also suitable cloning or expression hosts for antibody-encoding vectors, including fungal and yeast strains whose glycosylation pathways have been "humanized" to produce antibodies with partially or fully human glycosylation patterns. Suitable host cells for expressing (glycosylated) antibodies can also be derived from multicellular organisms (invertebrates and vertebrates); examples of invertebrate cells include plant and insect cells. Many baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells; plant cell cultures can also be used as hosts, for example, US5959177, US6040498, US6420548, US7125978 and US6417429; vertebrate cells can also be used as hosts, such as mammalian cell lines adapted for growth in suspension. Other examples of suitable mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293T cells); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells; MRC 5 cells; and FS4 cells. Other suitable mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells; and myeloma cell lines such as Y0, NS0, and Sp2 / 0. For review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki, P. and Wu, AM, Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2004), pp. 255-268.

[0502] Immunoconjugates

[0503] The present disclosure also provides immunoconjugates comprising an antigen binding molecule conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins of bacterial, fungal, plant, or animal origin, enzymatically active toxins, or fragments thereof), or radioactive isotopes.

[0504] Diagnostic and therapeutic compositions

[0505] In certain embodiments, the antigen binding molecules provided herein can be used to detect the presence of GPRC5D and / or CD3 in a biological sample. As used herein, the term "detection" encompasses quantitative or qualitative detection. In certain embodiments, the biological sample comprises cells or tissues, such as tumor tissue.

[0506] In one embodiment, an antigen binding molecule for use in a diagnostic or detection method is provided. In another aspect, a method for detecting the presence of GPRC5D and / or CD3 in a biological sample is provided. In certain embodiments, the method includes contacting the biological sample with an antigen binding molecule under suitable conditions and detecting whether a complex is formed between the detection reagent and the antigen. Such methods can be in vitro or in vivo methods. In one embodiment, an antigen binding molecule is used to select a subject suitable for treatment, for example, GPRC5D and / or CD3 are biomarkers for selecting patients.

[0507] Exemplary disorders that can be diagnosed using the antigen binding molecules of the disclosure include, for example, tumors or cancers.

[0508] In certain embodiments, labeled antigen binding molecules are provided. Labels include, but are not limited to, directly detected labels or modules (such as fluorescence, chromogenic, electron-dense, chemiluminescence, and radiolabels), and indirectly detected modules (e.g., modules indirectly detected via enzyme reactions or molecular interactions, such as enzymes or ligands).

[0509] In other aspects, a pharmaceutical composition comprising the antigen binding molecules is provided, for example, for any of the following methods of treatment. In one aspect, the pharmaceutical composition comprises any antigen binding molecules provided herein and a pharmaceutically acceptable carrier. In another aspect, the pharmaceutical composition comprises any antigen binding molecules provided herein and at least one other therapeutic agent.

[0510] The pharmaceutical composition of the antigen binding molecules described in this disclosure is prepared by mixing such antigen binding molecules with the desired purity with one or more optional pharmaceutically acceptable carriers in the form of a lyophilized composition or an aqueous solution. The preparation for in vivo administration is generally sterile. Sterility can be easily achieved, for example, by filtering through a sterile filtration membrane.

[0511] Treatment methods and administration routes

[0512] Any of the antigen binding molecules provided herein can be used in therapeutic methods.

[0513] In yet another aspect, the disclosure provides the purposes of antigen binding molecules in the manufacture or preparation of medicine. In one embodiment, the medicine is used to treat tumors or cancer. And the medicine exists in the form of an effective amount for the above-mentioned diseases. In some embodiments, the effective amount is a unit daily dose or a unit weekly dose. In one such embodiment, the purposes further includes administering an effective amount of at least one other therapeutic agent (such as one, two, three, four, five or six other therapeutic agents) to the subject. According to any of the above embodiments, "subject" can be a person.

[0514] In yet another aspect, a pharmaceutical composition comprising the antigen binding molecule is provided, for example, for use in any of the above pharmaceutical uses or treatment methods. In another embodiment, the pharmaceutical composition further comprises at least one additional therapeutic agent.

[0515] The antigen binding molecules of the present disclosure can be used alone or in combination with other agents for treatment. For example, the antigen binding molecules of the present disclosure can be co-administered with at least one additional therapeutic agent.

[0516] The antigen binding molecules of the present disclosure (and any other therapeutic agent) can be applied by any suitable means, including parenteral, intrapulmonary and intranasal, and if local treatment is needed, then intralesional application. Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration. Administration can be by any appropriate route, for example, by injection, such as intravenous or subcutaneous injection, which depends in part on whether administration is short-term or long-term. A variety of administration time schemes are contemplated herein, including but not limited to, single or multiple administrations at multiple time points, push administration and pulse infusion.

[0517] The antigen binding molecules of the present disclosure will be prepared, administered and used in a manner that meets good medical practice. The factors considered in this context include the specific disease for treatment, the specific mammal for treatment, the clinical condition of the individual patient, the cause of the disease, the delivery site of the reagent, the method of administration, the administration time arrangement and other factors known to medical practitioners. Antigen binding molecules do not need to but are optionally prepared together with one or more reagents currently used to prevent or treat the disease. The effective amount of such other reagents depends on the amount of the antigen binding molecules present in the pharmaceutical composition, the type of disease or treatment and other factors discussed above. These are usually used with the same dosage and administration route as described herein, or with about 1 to 99% of dosage described herein, or with any dosage, and are determined to be suitable any approach use by experience / clinical practice.

[0518] In order to prevent or treat disease, the appropriate dosage of the antigen binding molecules of the present disclosure (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of therapeutic molecule, the severity and course of the disease, whether to use for prevention or treatment purposes, previous treatment, the patient's clinical history and the response to the therapeutic molecule, and the judgment of the attending physician. The therapeutic molecule is appropriately administered to the patient once or through a series of treatments. Depending on the type and severity of the disease, the antigen binding molecules of about 1 μg / kg to 15mg / kg can be the initial candidate dose for administration to the patient, no matter whether, for example, by one or more separate administrations or by continuous infusion. A typical daily dose may be in the range of about 1 μg / kg to 100mg / kg or more, depending on the factors mentioned above. Accordingly, taking 50kg body weight as an example, an exemplary unit daily dose is 50 μg-5g.

[0519] Products

[0520] In another aspect of the present disclosure, a product is provided, the product comprising materials that can be used to treat, prevent and / or diagnose the above-mentioned conditions. The product comprises a container and a label or package insert on or in combination with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The container can be formed from various materials such as glass or plastic. The container is filled with a composition that is effective for treating, preventing and / or diagnosing the disease, either alone or in combination with another composition, and may have a sterile access port (for example, the container may be an intravenous solution bag or vial with a stopper pierceable by a hypodermic needle). At least one active agent in the composition is an antigen-binding molecule of the present disclosure. The label or package insert indicates that the composition is used to treat the selected condition. In addition, the product may comprise: (a) a first container containing a composition, wherein the composition comprises an antigen-binding molecule of the present disclosure; and (b) a second container containing a composition, wherein the composition comprises another cytotoxic agent or a therapeutic agent of other aspects. The product in this embodiment of the present disclosure may further comprise a package insert indicating that the composition can be used to treat a specific condition. Alternatively, or additionally, the product may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer. From a commercial and user perspective, it may further comprise other materials required, including other buffers, diluents, filters, needles, and syringes.

[0521] Examples and test cases

[0522] The present disclosure is further described below with reference to the following examples and test cases, but these examples and test cases are not intended to limit the scope of this disclosure. Experimental methods in the examples and test cases disclosed herein, where specific conditions are not specified, generally follow conventional conditions, such as those in the Cold Spring Harbor Laboratory Manual of Antibody Techniques and the Molecular Cloning Manual, or the conditions recommended by the raw material or product manufacturer. Reagents whose sources are not specified are commercially available reagents.

[0523] Example 1. Antigen-binding molecules containing titin chains / obscurin chains

[0524] The titin chain / obscurin chain disclosed herein can be derived from any suitable polypeptide, including polypeptides from WO2021139758 (incorporated herein by reference in its entirety) and CN202110527339.7, and patents to which they are priority documents (incorporated herein by reference in their entirety). A bispecific antibody was constructed, wherein CL is the kappa light chain constant region in WO2021139758, the amino acid sequences of the titin chain and obscurin chain are shown in Tables 3-1 and 3-2, the linker sequence includes GGGGS (SEQ ID NO: 90), ASTKG (SEQ ID NO: 209), or RTVAS (SEQ ID NO: 210), and the amino acid sequences of Fc1, Fc2, and CH1 in this example are shown below.

[0525] >Example 1-Fc1 (knob, SEQ ID NO: 92):

[0526] >Example 1-Fc2 (hole, SEQ ID NO: 93):

[0527] >Example 1-CH1 (SEQ ID NO: 91):

[0528] 1.1 DI bispecific antibodies

[0529] With reference to Example 5 of WO2021139758, DI bispecific antibodies against hNGF and hRANKL were constructed: DI-2 to DI-20, which comprised the first heavy chain, the second heavy chain, the first light chain, and the second light chain as described below:

[0530] First heavy chain: from N-terminus to C-terminus: [VH1-I]-[Linker 1]-[Obscurin chain]-[Fc2],

[0531] First light chain: from N-terminus to C-terminus: [VL1-I]-[Linker 2]-[Titin chain],

[0532] The second heavy chain: from N-terminus to C-terminus: [VH2-D]-[CH1]-[Fc1], and

[0533] Second light chain: from N-terminus to C-terminus: [VL2-D]-[CL];

[0534] Among them, VH1-I and VL1-I are the heavy chain variable region and light chain variable region of I0 in WO2021139758, respectively, and VH2-D and VL2-D are the heavy chain variable region and light chain variable region of D0 in WO2021139758, respectively. The structures of the obscurin chain, titin chain, linker 1, and linker 2 in the DI bispecific antibody in this example are shown in the table below.

[0535] Table 5. Correspondence between Obscurin Chain / Titin Chain and Linker in DI Bispecific Antibodies

[0536] Note: The numbers of titin chains and obscurin chains are shown in Table 3-1 and Table 3-2.

[0537] The binding activity of DI-2 to DI-20 bispecific antibodies to their antigens was detected using the method in Test Example 4 of WO2021139758. The thermal stability of the antibodies was studied. Research method: The concentration of the antibody was diluted to 5 mg / mL with PBS, and its thermal stability was determined using a high-throughput differential scanning fluorimeter (UNCHAINED, specification model: Unit). The experimental results showed that the binding activity of the modified bispecific antibody to the antigen did not change significantly; and compared with DI-2, the Tm1 (℃) and Tonset (℃) of DI-4 to DI-8, DI-10 to DI-16, and DI-20 were significantly improved, and the bispecific antibody had better thermal stability.

[0538] Table 6. Binding activity detection of DI bispecific antibodies

[0539] Table 7. Thermal stability test results of DI bispecific antibodies

[0540] A solution containing the DI bispecific antibody was prepared in a buffer solution of 10 mM acetic acid, pH 5.5, and 9% sucrose. The solution was incubated in a 40°C incubator for four weeks. After the incubation period, the antibody concentration was concentrated to the initial concentration and the solution was observed for precipitation. The results showed that the DI-2 bispecific antibody group exhibited precipitation, while DI-3 through DI-7 exhibited greater stability than DI-2.

[0541] Table 8. Precipitation of DI bispecific antibodies

[0542] 1.2 PL bispecific antibodies

[0543] PL bispecific antibodies against hPDL1 and hCTLA4 were constructed: PL-1 to PL-19, which comprise the first heavy chain, the second heavy chain, the first light chain, and the second light chain as described below:

[0544] First heavy chain: from N-terminus to C-terminus: [VH1-P]-[Linker 1]-[Obscurin chain]-[Fc1],

[0545] First light chain: from N-terminus to C-terminus: [VL1-P]-[Linker 2]-[Titin chain],

[0546] The second heavy chain: from N-terminus to C-terminus: [VH2-L]-[CH1]-[Fc2], and

[0547] Second light chain: from N-terminus to C-terminus: [VL2-L]-[CL];

[0548] Among them, VH1-P and VL1-P are the heavy chain variable region and light chain variable region of the h1831K antibody in WO2020177733, respectively, and the amino acid sequences of VH2-L and VL2-L are shown below.

[0549] >VH2-L (SEQ ID NO: 191):

[0550] >VL2-L (SEQ ID NO: 192):

[0551] The structures of the obscurin chain, titin chain, linker 1, and linker 2 in the PL bispecific antibody of this embodiment are shown in the table below.

[0552] Table 9. Correspondence between Obscurin Chain / Titin Chain and Linker in PL Bispecific Antibodies

[0553] Note: The numbers of titin chains and obscurin chains are shown in Table 3-1 and Table 3-2.

[0554] The binding activity of the PL bispecific antibody was tested using the ELISA method described in Test Example 4 of WO2021139758. The hPDL1 and hCTLA4 antigens were purchased from Sino Biology. The thermal stability of the antibody was investigated. Methods: The antibody was diluted to a concentration of 1.4-3 mg / mL in PBS, and its thermal stability was measured using a high-throughput differential scanning fluorimeter (UNCHAINED, specification model: Unit). The experimental results demonstrated that the PL bispecific antibody maintained good binding activity to the antigen. Furthermore, compared to PL-1, the Tm1 (°C), Tagg 266 (°C), and Tonset (°C) values ​​of PL-2 to PL-19 were significantly improved, indicating that the bispecific antibody exhibited superior thermal stability.

[0555] Table 10. Binding activity detection of PL bispecific antibodies

[0556] Table 11. Thermal stability test results of PL bispecific antibodies

[0557] 1.3 HJ bispecific antibodies

[0558] HJ bispecific antibodies against hIL5 and hTSLP were constructed: HJ-3 to HJ11, which comprise the first heavy chain, the second heavy chain, the first light chain, and the second light chain as described below:

[0559] First heavy chain: from N-terminus to C-terminus: [VH1-H]-[Linker 1]-[Titin chain]-[Fc1],

[0560] First light chain: from N-terminus to C-terminus: [VL1-H]-[Linker 2]-[Obscurin chain],

[0561] The second heavy chain: from N-terminus to C-terminus: [VH2-J]-[CH1]-[Fc2], and

[0562] Second light chain: from N-terminus to C-terminus: [VL2-J]-[CL];

[0563] Among them, VH1-H and VL1-H are the heavy chain variable region and light chain variable region of H0 in WO2021139758, respectively, and VH2-J and VL2-J are the heavy chain variable region and light chain variable region of J1 in WO2021139758, respectively. The structures of the obscurin chain, titin chain, linker 1, and linker 2 in the HJ bispecific antibody in this example are shown in the table below.

[0564] Table 12. Correspondence between Obscurin Chain / Titin Chain and Linker in HJ Bispecific Antibodies

[0565] The antigen binding activity of the HJ bispecific antibody was detected with reference to the method in Test Example 4 of WO2021139758. The thermal stability of the antibody was studied as follows: a diluted HJ bispecific antibody solution was prepared with a buffer solution of 10 mM acetic acid, pH 5.5, and 9% sucrose. The bispecific antibody was then concentrated by ultrafiltration to obtain HJ bispecific antibody solutions of different concentrations (see Table 13-2 for the concentration of the HJ bispecific antibody). The concentrated solution was then incubated in a 40°C incubator. The SEC purity of the samples was tested on day 0 (i.e., before the start of incubation at 40°C, D0), day 7 (7th day of incubation at 40°C, D7), day 14 (14th day of incubation at 40°C, D14), day 21 (21st day of incubation at 40°C, D21), and day 28 (28th day of incubation at 40°C, D28). After incubation at 40°C for 28 days, the samples were immediately sampled for CE-SDS purity. The experimental results showed that the antigen binding activity of the HJ bispecific antibodies constructed in the present disclosure did not change significantly; and compared with HJ-3, the thermal stability of the HJ-5 to HJ-11 bispecific antibodies was better.

[0566] Table 13-1. Binding activity detection of HJ bispecific antibodies

[0567] Table 13-2. Results of accelerated stability test of HJ bispecific antibody

[0568] Example 2. Construction and identification of cell lines expressing recombinant human GPRC5D and cynomolgus monkey GPRC5D

[0569] To screen antibodies that can bind well to cell surface GPRC5D, the present disclosure constructed CHOK1-humanGPRC5D, HEK293-humanGPRC5D, CHOK1-cynoGPRC5D, and HEK293-cynoGPRC5D cell lines expressing human GPRC5D or cynomolgus monkey GPRC5D. The full-length gene of human GPRC5D or cynomolgus monkey GPRC5D was cloned into the mammalian cell expression vector pCDH, and HEK293T cells were co-transfected with pVSV-G, pCMV-dR8.91, and pCDH-humanGPRC5D or pCDH-cynoGPRC5D plasmids. CRL-11268) packaged virus, and 48 hours after transfection, the virus was collected and infected CHOK1 cells ( CCL-61) and HEK293 cells ( CRL-1573). Monoclonal cells highly expressing human GPRC5D or cynomolgus macaque GPRC5D were obtained by flow cytometry 72 hours after infection.

[0570] Example 3. Preparation of mouse anti-human GPRC5D monoclonal antibody

[0571] CHOK1-humanGPRC5D and CHOK1-cynoGPRC5D cells were used to cross-immunize SJL mice. After 7 immunizations, blood was collected to determine the titer of the antibody in the serum. Mice with high antibody titers in the serum and titers approaching a plateau were selected for spleen cell fusion. The fused hybridoma cells were plated in 96-well cell culture plates and cultured in a 37°C, 5% CO2 incubator. The cell culture supernatant was detected by mirrorball and flow cytometry (FACS). The screened positive clones were amplified, frozen, and subcloned two to three times until a single cell clone was obtained. The selected hybridoma clones were further prepared and purified using a serum-free cell culture method. The obtained hybridoma antibodies were tested for binding to CHOK1-humanGPRC5D, CHOK1-cynoGPRC5D, and CHOK1 cells using FACS (see Test Example 1 of this disclosure for the method), and hybridoma cell lines mAb1, mAb24, mAb30, and mab45 with good human-monkey cross-binding activity and no non-specific binding were selected.

[0572] The sequences of the monoclonal antibodies from hybridoma cell lines mAb1, mAb24, mAb30, and mAb45 were cloned as follows: Hybridoma cells in logarithmic growth phase were harvested, RNA was extracted using Trizol (Invitrogen, Cat# 15596-018), and reverse transcribed into cDNA. PCR amplification of the cDNA was performed using the template and then sequenced by a sequencing company. The resulting DNA sequences corresponded to the amino acid sequences of the antibody variable regions as follows:

[0573] Amino acid sequence of the heavy chain variable region of mAb1:

[0574] Amino acid sequence of the light chain variable region of mAb1:

[0575] Amino acid sequence of the heavy chain variable region of mAb24:

[0576] Amino acid sequence of the light chain variable region of mAb24:

[0577] Amino acid sequence of the heavy chain variable region of mAb30:

[0578] Amino acid sequence of the light chain variable region of mAb30:

[0579] Amino acid sequence of the heavy chain variable region of mAb45:

[0580] Amino acid sequence of the light chain variable region of mAb45:

[0581] Note: The underlined part is CDR according to Kabat numbering convention, and the rest are FR.

[0582] Table 14. CDRs of GPRC5D Antibody

[0583] Note: The CDRs in the table are confirmed according to the Kabat numbering system.

[0584] Example 4. Humanized design of anti-human GPRC5D monoclonal antibody

[0585] Humanization of murine monoclonal antibodies is performed using methods well-documented in the field. Briefly, based on the representative VH / VL CDR structures of the murine antibody, homologous sequences of the light chain variable region (VL) and heavy chain variable region (VH) are searched from human germline databases. The murine antibody CDR regions are then transplanted onto a human template, and some VL and VH residues are mutated. The murine antibody constant region is then replaced with a human constant region to yield the final humanized molecule.

[0586] 1. Humanization of mAb1

[0587] The humanized heavy chain variable region of mAb1 uses IGHV3-21*01 for FR1, FR2, and FR3, and IGHJ6*01 for FR4. The light chain variable region uses IGKV2-29*02 for FR1, FR2, and FR3, and IGKJ2*01 for FR4. Optionally, amino acids at positions 49, 56, 57, and / or 93 of the heavy chain variable region of the humanized antibody are substituted, and / or amino acids at positions 2, 28, 29, and / or 45 of the light chain variable region of the humanized antibody are substituted.

[0588] Table 15. Amino acid substitutions of humanized mAb1

[0589] Note: Exemplarily, Q45K means that according to the Kabat numbering system, the Q at position 45 is mutated back to K. And so on.

[0590] The sequence of the antibody variable region is as follows (the underlined part is CDR, the same below):

[0591] >hu1H1 (SEQ ID NO: 33):

[0592] >hu1H2 (SEQ ID NO: 34):

[0593] >hu1H3 (SEQ ID NO: 35):

[0594] >hu1L1 (SEQ ID NO: 36):

[0595] >hu1L2 (SEQ ID NO: 37):

[0596] >hu1L3 (SEQ ID NO: 38):

[0597] >hu1L4 (SEQ ID NO: 39):

[0598] >hu1L5 (SEQ ID NO: 40):

[0599] >hu1L6 (SEQ ID NO: 41):

[0600] The amino acid sequences of the replaced CDRs in the humanized antibodies are shown in the table below:

[0601] Table 16. Amino acid sequences of hu1 replaced CDRs

[0602] 2. Humanization of mAb24

[0603] The humanized heavy chain variable region of mAb24 utilizes IGHV1-46*01 for FR1, FR2, and FR3, and IGHJ6*01 for FR4. The light chain variable region utilizes IGKV2-30*02 for FR1, FR2, and FR3, and IGKJ4*01 for FR4. Optionally, amino acids 1, 24, 37, 69, 71, 73, and / or 93 of the heavy chain variable region of the humanized antibody are substituted, and / or amino acids 4, 28, 29, 36, and / or 37 of the light chain variable region of the humanized antibody are substituted.

[0604] Table 17. Amino acid substitutions of humanized mAb 24

[0605] Note: Exemplarily, M4L means that according to the Kabat numbering system, position 4 M is mutated back to L. And so on.

[0606] The sequences of the antibody variable regions are as follows:

[0607] >hu24H1 (SEQ ID NO: 42):

[0608] >hu24H2 (SEQ ID NO: 43):

[0609] >hu24H3 (SEQ ID NO: 44):

[0610] >hu24L1 (SEQ ID NO: 45):

[0611] >hu24L2 (SEQ ID NO: 46):

[0612] >hu24L3 (SEQ ID NO: 47):

[0613] >hu24L4 (SEQ ID NO: 48):

[0614] >hu24L5 (SEQ ID NO: 49):

[0615] >hu24L6 (SEQ ID NO: 50):

[0616] The amino acid sequences of the replaced CDRs in the humanized antibodies are shown in the table below:

[0617] Table 18. Amino acid sequences of hu24 replaced CDRs

[0618] 3. Humanization of mAb30

[0619] The humanized heavy chain variable region of mAb30 utilizes IGHV1-3*01 for FR1, FR2, and FR3, and IGHJ6*01 for FR4. The light chain variable region utilizes IGKV1-12*01 for FR1, FR2, and FR3, and IGKJ2*01 for FR4. Optionally, amino acids 1, 28, 43, 45, 54, 69, 71, 73, and / or 93 of the heavy chain variable region of the humanized antibody are substituted, and / or amino acids 43, 46, and / or 85 of the light chain variable region of the humanized antibody are substituted.

[0620] Table 19. Amino acid substitutions of humanized mAb 30

[0621] Note: Exemplarily, L46A means that according to the Kabat numbering system, position 46 L is mutated back to A. And so on.

[0622] The sequences of the antibody variable regions are as follows:

[0623] >hu30H1 (SEQ ID NO: 51):

[0624] >hu30H2 (SEQ ID NO: 52):

[0625] >hu30H3 (SEQ ID NO: 53):

[0626] >hu30H4 (SEQ ID NO: 54):

[0627] >hu30H5 (SEQ ID NO: 55):

[0628] >hu30L1 (SEQ ID NO: 56):

[0629] >hu30L2 (SEQ ID NO: 57):

[0630] The amino acid sequences of the replaced CDRs in the humanized antibodies are shown in the table below:

[0631] Table 20. Amino acid sequences of hu30 replaced CDRs

[0632] 4. Humanization of mAb45

[0633] The humanized heavy chain variable region of mAb45 utilizes IGHV3-7*01 for FR1, FR2, and FR3, and IGHJ6*01 for FR4. The light chain variable region utilizes IGKV2-28*01 for FR1, FR2, and FR3, and IGKJ4*01 for FR4. Optionally, amino acids at positions 30, 38, 49, 74, 75, 76, and / or 77 of the heavy chain variable region of the humanized antibody are substituted, and / or amino acids at positions 2, 28, 29, 45, 63, and / or 76 of the light chain variable region of the humanized antibody are substituted.

[0634] Table 21. Amino acid substitutions of humanized mAb45

[0635] Note: Exemplarily, I2V means that according to the Kabat numbering system, position 2 I is mutated back to V. And so on.

[0636] The sequences of the antibody variable regions are as follows:

[0637] >hu45H1 (SEQ ID NO: 58):

[0638] >hu45H2 (SEQ ID NO: 59):

[0639] >hu45H3 (SEQ ID NO: 60):

[0640] >hu45H4 (SEQ ID NO: 61):

[0641] >hu45H5 (SEQ ID NO: 62):

[0642] >hu45H6 (SEQ ID NO: 63):

[0643] >hu45H7 (SEQ ID NO: 64):

[0644] >hu45H8 (SEQ ID NO: 65):

[0645] >hu45H9 (SEQ ID NO: 66):

[0646] >hu45H10 (SEQ ID NO: 67):

[0647] >hu45H11 (SEQ ID NO: 68):

[0648] >hu45L1 (SEQ ID NO: 69):

[0649] >hu45L2 (SEQ ID NO: 70):

[0650] >hu45L3 (SEQ ID NO: 71):

[0651] >hu45L4 (SEQ ID NO: 72):

[0652] >hu45L5 (SEQ ID NO: 73):

[0653] >hu45L6 (SEQ ID NO: 74):

[0654] >hu45L7 (SEQ ID NO: 75):

[0655] The amino acid sequences of the replaced CDRs in the humanized antibodies are shown in the table below:

[0656] Table 22. Amino acid sequences of hu45 replaced CDRs

[0657] Example 5. Construction of chimeric antibodies

[0658] The variable region sequences of the murine anti-GPRC5D antibodies mAb1, mAb24, mAb30, and mAb45 were combined with the light chain constant region of SEQ ID NO:96 and the heavy chain constant region of SEQ ID NO:215, respectively, to obtain chimeric antibodies Chi-1, Chi-24, Chi-30, and Chi-45. For example, Chi-1 represents a chimeric antibody comprising the murine heavy chain variable region, light chain variable region, and the constant region of mAb1, and so on. The sequences of the heavy chain constant region and light chain constant region of the chimeric antibodies are as follows:

[0659] >Heavy chain constant region sequence (SEQ ID NO: 215):

[0660] The heavy chain sequence of Chi-1 (SEQ ID NO: 216):

[0661] Light chain sequence of Chi-1 (SEQ ID NO: 217):

[0662] The heavy chain sequence of Chi-24 (SEQ ID NO: 218):

[0663] The light chain sequence of Chi-24 (SEQ ID NO: 219):

[0664] The heavy chain sequence of Chi-30 (SEQ ID NO: 220):

[0665] Light chain sequence of Chi-30 (SEQ ID NO: 221):

[0666] The heavy chain sequence of Chi-45 (SEQ ID NO: 222):

[0667] The light chain sequence of Chi-45 (SEQ ID NO: 223):

[0668] Example 6. Preparation and identification of anti-GPRC5D / CD3 bispecific antibodies

[0669] The CD3 binding molecules disclosed herein can be derived from any suitable antibody. Particularly suitable antibodies are described, for example, in International Application No. PCT / CN2019 / 123548 (incorporated herein by reference in its entirety). Specifically, the embodiments disclosed herein employ S107E.

[0670] Table 23. CDRs of S107E

[0671] The sequence of the S107E variable region is as follows:

[0672] >S107E-VH (SEQ ID NO: 82):

[0673] >S107E-VL (SEQ ID NO: 83):

[0674] The humanized anti-GPRC5D antibody variable region was combined with the variable region of the anti-CD3 antibody S107E, IgG1 (CH1), obscurin, titin, and the IgG1 mutant IgG1 (AA, L234A / L235A), respectively, to form several different bispecific antibody formats, namely Formula 2, Formula 2-OG4S, Formula 4, Formula 4-OG4S, and Formula 11.

[0675] Formula 2 (i.e., F2) is an asymmetric structure molecule containing four chains:

[0676] Chain 1: VH (anti-GPRC5D)-IgG1 (CH1)-IgG1Fc (Knob);

[0677] Chain 2: VL (anti-GPRC5D)-CL;

[0678] Chain 3 (OB(A1B0)-linker1-Hole):

[0679] VH(S107E)-linker1-Obscurin(A1B0)-IgG1Fc(Hole);

[0680] Chain 4 (VL-linker2-Titin(A1B0)): VL(S107E)-linker2-Titin(A1B0), a schematic diagram of which is shown in FIG1A (OB represents Obscurin).

[0681] in:

[0682] >linker1 or linker2: GGGGS (SEQ ID NO: 90)

[0683] >OB(A1B0)-linker1-Hole(SEQ ID NO: 84):

[0684] Note: CD3 binding domain CDRs obtained according to Kabat numbering rules are The heavy chain constant region is marked with "italics", and linker1 is marked with Obscurin (A1B0) was labeled with Marker, mutation sites (L234A, L235A, Y349C, T366S, L368A, Y407V) were marked with mark.

[0685] >VL-linker2-Titin(A1B0)(SEQ ID NO: 85):

[0686] Note: CD3 binding domain CDRs obtained according to Kabat numbering rules are tag, linker2 Marker, Titin (A1B0) mark.

[0687] Formula 2-0G4S (i.e., F2-0G4S) is an asymmetric molecule consisting of four chains:

[0688] Chain 1: VH (anti-GPRC5D)-IgG1 (CH1)-IgG1Fc (Knob);

[0689] Chain 2: VL (anti-GPRC5D)-CL;

[0690] Chain 3 (OB(A0B2)-Hole): VH(S107E)-OB(A0B2)-IgG1Fc(Hole);

[0691] Chain 4 (VL-Titin(A0B2)): VL(S107E)-Titin(A0B2), a schematic diagram of which is shown in FIG1B (OB stands for Obscurin).

[0692] in:

[0693] >OB(A0B2)-Hole(SEQ ID NO: 86):

[0694] Note: CD3 binding domain CDRs obtained according to Kabat numbering rules are The heavy chain constant region is marked with "italics", and Obscurin (A0B2) is marked with Markers, mutation sites (L234A, L235A, Y349C, T366S, L368A, Y407V) were used mark.

[0695] >VL-Titin(A0B2)(SEQ ID NO: 87):

[0696] Note: CD3 binding domain CDRs obtained according to Kabat numbering rules are Marker, Titin (A0B2) mark.

[0697] Formula 4 (i.e., F4) is an asymmetric structure molecule containing four chains:

[0698] Chain 1 (OB(A1B0)-linker3-Knob): VH(S107E)-linker3-OB(A1B0)-IgG1Fc(Knob);

[0699] Chain 2 (VL-linker4-Titin(A1B0)): VL(S107E)-linker4-Titin(A1B0);

[0700] Chain 3: VH (anti-GPRC5D)-IgG1 (CH1)-IgG1 Fc (Hole);

[0701] Chain 4: VL (anti-GPRC5D)-CL;

[0702] A schematic diagram thereof is shown in FIG1C (OB stands for Obscurin).

[0703] >linker3 or linker4: GGGGS (SEQ ID NO: 90)

[0704] >OB(A1B0)-linker3-Knob(SEQ ID NO: 88):

[0705] Note: CD3 binding domain CDRs obtained according to Kabat numbering rules are The heavy chain constant region is marked with "italics", and Obscurin (A1B0) is marked with Marker, mutation sites (L234A, L235A, S354C, T366W) are marked with Mark, linker3 uses mark.

[0706] >VL-linker4-Titin(A1B0)(SEQ ID NO:85):

[0707] Note: CD3 binding domain CDRs obtained according to Kabat numbering rules are Marker, Titin (A1B0) Mark, linker4 uses mark.

[0708] Formula 4-0G4S (i.e., F4-0G4S) is an asymmetric molecule consisting of four chains:

[0709] Chain 1 (OB(A0B2)-Knob): VH(S107E)-OB(A0B2)-IgG1Fc(Knob);

[0710] Chain 2 (VL-Titin(A0B2)): VL(S107E)-Titin(A0B2);

[0711] Chain 3: VH (anti-GPRC5D)-IgG1 (CH1)-IgG1 Fc (Hole);

[0712] Chain 4: VL (anti-GPRC5D)-CL;

[0713] A schematic diagram thereof is shown in FIG1D (OB stands for Obscurin).

[0714] >Ob(A0B2)-Knob(SEQ ID NO: 89):

[0715] Note: CD3 binding domain CDRs obtained according to Kabat numbering rules are The heavy chain constant region is marked with "italics", and Obscurin (A0B2) is marked with Marker, mutation sites (L234A, L235A, S354C, T366W) are marked with mark.

[0716] >VL-Titin(A0B2)(SEQ ID NO: 87):

[0717] Note: CD3 binding domain CDRs obtained according to Kabat numbering rules are Marker, Titin (A0B2) mark.

[0718] in:

[0719] >IgG1(CH1) (SEQ ID NO:91):

[0720] >IgG1Fc(Knob)(SEQ ID NO:92):

[0721] >IgG1Fc(Hole)(SEQ ID NO:93):

[0722] Formula 11 (ie, F11) is a symmetrical structure molecule comprising two identical heavy chains (chain 1) and two identical light chains (chain 2).

[0723] Chain 1 (heavy chain):

[0724] VH(anti-GPRC5D)-IgG1(CH1)-VH(S107E)-linker5-VL(S107E)-linker6-IgG1(AA)Fc;

[0725] Chain 2 (light chain): VL(anti-GPRC5D)-CL; a schematic diagram thereof is shown in FIG1E .

[0726] in:

[0727] >linker5: GGGGSGGGGSGGGGS (SEQ ID NO: 94)

[0728] >linker6: GGG (SEQ ID NO: 95)

[0729] >IgG1(CH1) (SEQ ID NO:91):

[0730] >CL (SEQ ID NO: 96):

[0731] >IgG1(AA)Fc(SEQ ID NO:97):

[0732] Based on the humanized antibody amino acid sequences of mAb1, mAb24, mAb30, and mAb45 antibodies, the following bispecific antibodies were constructed.

[0733] Table 24. Bispecific antibodies of the present disclosure

[0734] Note: In Table 24, F11-1 indicates that the molecule uses the variable region of mAb1 and its humanized antibody as the GPRC5D binding domain and uses Formula 11 as the molecular structure; F2-1 indicates that the molecule uses the variable region of mAb1 and its humanized antibody as the GPRC5D binding domain and uses Formula 2 as the molecular structure, and so on.

[0735] The specific amino acid sequence is as follows:

[0736] Chain 1 of F11-1, F11-2, and F11-3 (>hu1H2-F11-1 (SEQ ID NO: 98)):

[0737] Chain 1 of F11-4, F11-5, and F11-6 (>hu1H3-F11-1 (SEQ ID NO: 99)):

[0738] Chain 2 of F11-1 and F11-4 (>hu1L1-CL (SEQ ID NO: 100)):

[0739] Chain 2 of F11-2 and F11-5 (>hu1L3-CL (SEQ ID NO: 101)):

[0740] Chain 2 of F11-3 and F11-6 (>hu1L4-CL (SEQ ID NO: 102)):

[0741] Chain 1 of F11-7, F11-8, and F11-9 (>hu24H2-F11-1 (SEQ ID NO: 103)):

[0742] Chain 1 of F11-10, F11-11, and F11-12 (>hu24H3-F11-1 (SEQ ID NO: 104)):

[0743] Chain 2 of F11-7 and F11-10 (>hu24L2-CL (SEQ ID NO: 105)):

[0744] Chain 2 of F11-8 and F11-11 (>hu24L5-CL (SEQ ID NO: 106)):

[0745] Chain 2 of F11-9 and F11-12 (>hu24L6-CL (SEQ ID NO: 107)):

[0746] Chain 1 of F11-13 and F11-15 (>hu30H4-F11-1 (SEQ ID NO: 108)):

[0747] Chain 1 of F11-14 and F11-16 (>hu30H5-F11-1 (SEQ ID NO: 109)):

[0748] Chain 2 of F11-13 and F11-14 (>hu30L1-CL (SEQ ID NO: 110)):

[0749] Chain 2 of F11-15 and F11-16 (>hu30L2-CL (SEQ ID NO: 111)):

[0750] Chain 3 of F4-1 (>hu45H4-CH1-Hole (SEQ ID NO: 112)):

[0751] Chain 3 of F4-2 (>hu45H5-CH1-Hole (SEQ ID NO: 113)):

[0752] Chain 3 of F4-3 (>hu45H7-CH1-Hole (SEQ ID NO: 114)):

[0753] Chain 3 of F4-4 (>hu45H8-CH1-Hole (SEQ ID NO: 115)):

[0754] Chain 3 of F4-5 (>hu45H10-CH1-Hole (SEQ ID NO: 116)):

[0755] Chain 4 of F4-1, F4-2, F4-3, F4-4, F4-5 (>hu45L7-CL (SEQ ID NO: 117)):

[0756] Chain 1 of F2-0G4S-1 (>hu1H3-CH1-Knob (SEQ ID NO: 118)):

[0757] Chain 3 of F4-8 (>hu1H3-CH1-Hole (SEQ ID NO: 119)):

[0758] Chain 1 of F2-2 (>hu24H3-CH1-Knob (SEQ ID NO: 120)):

[0759] Chain 3 of F4-6 (>hu24H3-CH1-Hole (SEQ ID NO: 121)):

[0760] Chain 1 of F2-3 (>hu30H5-CH1-Knob (SEQ ID NO: 122)):

[0761] Chain 3 of F4-7 (>hu30H5-CH1-Hole (SEQ ID NO: 123)):

[0762] Chain 1 of F2-4 (>hu45H10-CH1-Knob (SEQ ID NO: 124)):

[0763] Chain 1 of F11-17 (>Chi-1-F11-1) (SEQ ID NO: 224):

[0764] Chain 2 of F11-17 (>Chi-1 VL-CL) (SEQ ID NO: 217):

[0765] Chain 1 of F11-18 (>Chi-24-F11-1) (SEQ ID NO: 225):

[0766] Chain 2 of F11-18 (>Chi-24VL-CL) (SEQ ID NO: 219):

[0767] Chain 1 of F11-19 (>Chi-30-F11-1) (SEQ ID NO: 226):

[0768] Chain 2 of F11-19 (>Chi-30VL-CL) (SEQ ID NO: 221):

[0769] Chain 3 of F4-9 (>Chi-45-CHI-Hole) (SEQ ID NO: 227):

[0770] Chain 4 of F4-9 (>Chi-45VL-CL) (SEQ ID NO: 223):

[0771] The positive control molecule JNJ-64407564 used in this disclosure has the following sequence (derived from WO2018017786):

[0772] >Heavy chain (anti-GPRC5D) (SEQ ID NO: 125):

[0773] >Light chain (anti-GPRC5D) (SEQ ID NO: 126):

[0774] >Heavy chain (anti-CD3E) (SEQ ID NO: 127):

[0775] >Light chain (anti-CD3E) (SEQ ID NO: 128):

[0776] >Heavy chain variable region of the humanized anti-GPRC5D antibody in JNJ-64407564 (SEQ ID NO: 228):

[0777] >Light chain variable region of the humanized anti-GPRC5D antibody in JNJ-64407564 (SEQ ID NO: 229):

[0778] >Heavy chain of JNJ7564-huIgG1 (SEQ ID NO: 230):

[0779] >Light chain of JNJ7564-huIgG1 (SEQ ID NO: 231):

[0780] Test Case

[0781] Test Example 1. FACS determination of the affinity of GPRC5D / CD3 bispecific antibody for GPRC5D

[0782] To test the binding ability of the disclosed GPRC5D / CD3 bispecific antibody to GPRC5D, this test example used flow cytometry to detect the binding of the GPRC5D / CD3 bispecific antibody to the human multiple myeloma cell line MM.1R ( The binding capacity of CRL-2975) and the stable transgenic cell line CHOK1-cynoGPRC5D expressing cynomolgus macaque GPRC5D was tested as follows: the above cells were cultured in complete medium with 10% FBS in a 37°C, 5% CO2 incubator for 2 days, and the number of cells per well was 1×10 5 Add cells to the cell plate, centrifuge at 300g for 5 minutes, and wash once with 1% BSA. Dilute the antibody serially to 8 concentrations, add 100μL to each well of the cell plate, incubate at 4℃ for 1 hour, wash once with 1% BSA, add 100μL FITC-Goat Anti-human IgG Fc fluorescent secondary antibody dilution (1:400) to each well, and incubate at 4℃ for 1 hour. Wash the plate three times with 1% BSA, add 100μL PBS to each well and read the plate. EC values ​​of each antibody binding to the corresponding cells 50 (nM) are shown in the table below.

[0783] Table 25-1. Determination of the ability of chimeric antibodies to bind to GPRC5D

[0784] Note: JNJ7564-huIgG1 is an antibody obtained by combining the variable region sequence of the humanized anti-GPRC5D antibody in JNJ-64407564 with the light chain constant region shown in SEQ ID NO: 96 and the heavy chain constant region shown in SEQ ID NO: 215; "-" indicates no binding was detected.

[0785] Table 25-2. Determination of antibody binding ability to GPRC5D

[0786] Table 25-3. Determination of antibody binding ability to GPRC5D

[0787] Table 25-4. Determination of antibody binding ability to GPRC5D Note: “-” indicates no binding was detected.

[0788] Table 25-5. Determination of antibody binding ability to GPRC5D Note: “-” indicates no binding was detected.

[0789] Table 25-6. Determination of antibody binding ability to GPRC5D Note: “-” indicates no binding was detected.

[0790] Results showed that various GPRC5D monoclonal antibodies or GPRC5D- / CD3 bispecific antibodies constructed using the GPRC5D antibodies screened in this disclosure all exhibited strong binding to membrane-surface GPRC5D and demonstrated good cross-binding activity with cynoGPRC5D. JNJ-64407564 exhibited weaker binding to human GPRC5D than the antibodies disclosed in this disclosure, primarily as evidenced by very low binding response values ​​and extremely weak, almost undetectable, affinity for cynoGPRC5D.

[0791] Test Example 2. ELISA determination of the binding epitope between GPRC5D / CD3 bispecific antibody and GPRC5D

[0792] To determine the binding epitope of the disclosed GPRC5D / CD3 bispecific antibody to GPRC5D, four extracellular domain peptides of human GPRC5D were synthesized: the amino-terminal peptide (N-terminal peptide), the E2 peptide, the E3 peptide, and the E4 peptide (synthesized by GenScript). The peptides were biotinylated and prepared in two forms: lacking and containing intramolecular disulfide bonds. The sequences are shown in Table 26. Steptavidin (Sigma, SA101) was coated onto an Elisa plate (Corning 3590), incubated at 37°C for 2 hours, and then washed. Nonspecific binding sites were blocked with PBS containing 5% skim milk, incubated at 37°C for 2 hours, and then washed. 100 μL of peptide diluted in PBS containing 1% BSA was added to each well. The plate was incubated at 37°C for 1 hour, and then washed. 100 μL of GPRC5D / CD3 antibody diluted to 0.003 nM-300 nM in PBS containing 1% BSA was added to each well. The plate was incubated at 37°C for 1 hour, and then washed. Goat anti-human IgG (H+L)-HRP (Jackson ImmunoResearch, 209-035-088) was added. The plate was incubated at 37°C for 1 hour, and then washed. 100 μL of TMB (KPL, 5120-0077) was added to each well. After color development for 5 minutes, 1 M H2SO4 was added to terminate the color development, and the OD was measured. 450 The specific results are shown in Table 27.

[0793] Table 26. Four extracellular domain peptide sequences of human GPRC5D

[0794] Table 27. Determination of the ability of F2-0G4S-1 and F4-0G4S-1 to bind to GPRC5D 4 extracellular domain peptides Note: “-” indicates no binding was detected.

[0795] The results showed that the GPRC5D / CD3 bispecific antibodies F2-0G4S-1 and F4-0G4S-1 disclosed herein bound to the amino-terminal peptide sequence of human GPRC5D, regardless of whether the peptides formed intramolecular disulfide bonds. Furthermore, all tested antibodies did not bind to the E2, E3, and E4 peptides. These results indicate that the binding epitope of the GPRC5D / CD3 bispecific antibodies F2-0G4S-1 and F4-0G4S-1 disclosed herein to GPRC5D is located in the amino-terminal region of human GPRC5D.

[0796] Test Example 3. FACS determination of cross-binding between GPRC5D / CD3 bispecific antibody and GPCRA and GPCRB family members

[0797] To test whether the disclosed GPRC5D / CD3 bispecific antibody cross-binds with GPCRA and GPCRB family members, this test example used flow cytometry to detect the binding ability of the GPRC5D / CD3 bispecific antibody to CHOK1-human CCR8 cells expressing human CCR8 (GPCR A family) (constructed with reference to Example 2) and CHOK1-human GIPR cells expressing human GIPR (GPCR B family) (constructed with reference to Example 2). Specifically, the above cells were cultured in DMEF / 12K medium containing 10% FBS and placed in a 37°C, 5% CO2 incubator for 2 days. The number of cells per well was 1×10 5 Cells were added to the cell plate, centrifuged at 300g for 5 minutes, and washed once with 1% BSA. Antibody was serially diluted to eight concentrations, and 100 μL was added to each well of the cell plate. The plate was incubated at 4°C for 1 hour. The plate was washed once with 1% BSA, and 100 μL of FITC-Goat Anti-human IgG Fc fluorescent secondary antibody diluted in buffer (1:400) was added to each well. The plate was incubated at 4°C for 1 hour. The plate was washed three times with 1% BSA, and 100 μL of PBS was added to each well for reading.

[0798] >Human CCR8 antigen (SEQ ID NO: 211):

[0799] >Human GIPR antigen (SEQ ID NO: 212):

[0800] The results showed that the GPRC5D / CD3 bispecific antibodies F2-1, F2-0G4S-1, F4-6 and F4-0G4S-1 disclosed herein did not bind to human CCR8 and human GIPR, indicating their good specificity.

[0801] Test Example 4. In vitro cytotoxic activity of the bispecific antibodies disclosed herein

[0802] This test example studies the cytotoxic activity of the bispecific antibody disclosed herein as a T cell engagement molecule against tumor cells. The cell line H929 expressing GPRC5D and the Daudi cell line not expressing GPRC5D were used as target cells to detect the target-specific cytotoxic activity of the bispecific antibody disclosed herein. Fresh PBMC (purchased from Miaoshun Biotechnology Co., Ltd.) was centrifuged at 300g for 10 minutes, the supernatant was discarded, and the suspension was resuspended in 1640+10% FBS (liquid A) containing 200U IL2 to form a 2E6 / mL cell suspension, and placed in a culture flask for overnight culture. After overnight activation, the PBMCs were collected and centrifuged and resuspended in 1640+4% FBS without phenol red. After re-centrifugation, they were resuspended and counted, and the cell number was adjusted to 6.25E5 cells / mL. 60μL was added to each well (the number of PBMC cells in each well was 37,500). Target cells NCI-H929 (ATCC, CRL-9068) were harvested and centrifuged at 1000 rpm for 3 minutes. The cell count was adjusted to 1.25E5 cells / mL, and 60 μL was added to each well (7500 target cells per well), ensuring an E:T ratio of 5:1. The antibody was diluted in phenol red-free complete medium with a starting concentration of 500 nM (5× final concentration). Nine 10-fold dilutions were made, and 30 μL was added to each well. The cells were then incubated at 37°C, 5% CO2 for 48 hours. Before detection, 10 μL of medium was aspirated from two wells containing only target cells, and 10 μL of Lysis Solution (10×) was added. After lysis for 45 minutes, the culture plate was removed and centrifuged at 1000 rpm for 3 minutes. 50 μL of the supernatant was aspirated and transferred to a new 96-well plate (#3590). 50 μL of the dissolved CytoTox was added at a 1:1 ratio. Reagent, incubate at room temperature for 0.5 h, then add 50 μL of stop solution, and measure absorbance (490 nm) using FlexStation 3 (Molecular Devices). Specific results are shown in the table below.

[0803] Table 28. Cytotoxic activity of antibodies against NCI-H929 Note: EC 50 Ratio (relative to JNJ-64407564) = EC 50 (antibody to be tested) / EC 50 (JNJ-64407564).

[0804] The results showed that the GPRC5D / CD3 bispecific antibody disclosed herein had stronger NCI-H929 cytotoxic activity than JNJ-64407564; moreover, the cytotoxic activity of the GPRC5D / CD3 bispecific antibodies F2-2, F2-3, F4-6, F4-7, F2-0G4S-1, and F4-0G4S-1 disclosed herein was specific to the GPRC5D target, and no killing activity was detected in the Daudi cell line without GPRC5D expression, suggesting that the GPRC5D / CD3 bispecific antibody disclosed herein has better safety.

[0805] Test Example 5. Cytokine Release Level of GPRC5D / CD3 Bispecific Antibody

[0806] CD3 T cell engagement molecules can cause cytokine storms. Therefore, when developing CD3 T cell engagement molecules, it is necessary to keep cytokines, especially IL6, a factor that has nothing to do with drug efficacy but can cause side effects, at a low level. This test case studies the release levels of cytokines IFNγ and IL6 by the bispecific antibodies disclosed herein. Fresh PBMC (purchased from Miaoshun Biotechnology Co., Ltd.) was centrifuged at 300g for 10 minutes, the supernatant was discarded, and the cells were resuspended in 1640+10% FBS (liquid A) containing 200U IL2 to form a 2E6 / mL cell suspension, and placed in a culture flask for overnight culture. PBMC activated overnight were collected and centrifuged and resuspended in 1640+4% FBS without phenol red. After re-centrifugation, they were resuspended and counted, and the cell number was adjusted to 6.25E5 cells / mL. 60μL was added to each well (the number of PBMC cells in each well was 37,500). Target cells were harvested from NCI-H929 (ATCC, CRL-9068) or RPMI-8226 (ATCC, CRM-CCL-155) and centrifuged at 1000 rpm for 3 minutes. The cell count was adjusted to 1.25E5 cells / mL, and 60 μL was added to each well (7500 target cells per well), ensuring an E:T ratio of 5:1. Antibodies were diluted in phenol red-free complete medium at a starting concentration of 500 nM (5× final concentration). Nine 10-fold dilutions were made, and 30 μL was added to each well. Cells were then incubated at 37°C, 5% CO2 for 48 hours before use.

[0807] IL6 was detected by ELISA. The above cell samples were centrifuged at 1000 rpm for 3 minutes, 50 μL of cell supernatant was collected and diluted 6 times with universal specimen diluent, and the IL6 standard was also diluted 6 times. The diluted samples or different concentrations of standards (100 μL / well) were added to the detection plate, and the reaction wells were sealed with sealing tape. After incubation at 37°C for 90 minutes, the plate was washed 5 times, and the biotinylated antibody working solution (100 μL / well) was added. The reaction wells were sealed with new sealing tape. After incubation at 37°C for 60 minutes, the plate was washed 5 times. The enzyme conjugate working solution (100 μL / well) was added. The reaction wells were sealed with new sealing tape. After incubation at 37°C for 30 minutes, the plate was washed 5 times. 100 μL / well of colorimetric substrate (TMB) was added. Incubated at 37°C for 8 minutes in the dark, 100 μL / well of reaction stop solution was added, and the OD was measured immediately after mixing. 450 value (within 3 minutes).

[0808] IFNγ was detected using the HTRF method. The above cell samples were centrifuged at 1000rpm for 3 minutes, 50μL of cell supernatant was collected, the detection kit was balanced to room temperature, and the two detection antibodies in the kit were diluted with detection buffer (20-fold dilution). 16μL of the 20-fold diluted sample and IFNγ standard were placed in a 384-well plate, and 4μL of the diluted corresponding detection antibody was added; the sealing material was attached, shaken to mix, centrifuged at 1000rpm for 1 minute, incubated at room temperature overnight, centrifuged at 1000rpm for 1 minute, and the sealing material was removed. The absorbance values ​​at 665nm and 620nm were read using a PHERAstar multifunctional microplate reader, and the data were processed and analyzed using Graphpad Prism 5. The specific results are shown in the table below.

[0809] Table 29-1. IL-6 release in RPMI-8226 cytotoxicity assay Note: “-” indicates that the result was below the detection limit and not detected, the same below.

[0810] Table 29-2. IL-6 release in RPMI-8226 cytotoxicity assay

[0811] Table 29-3. IFNγ Release in RPMI-8226 Cytotoxicity Assay

[0812] Table 29-4. Release of IFNγ in RPMI-8226 cytotoxicity assay

[0813] Table 29-5. IL-6 release in NCI-H929 cytotoxicity assay

[0814] Table 29-6. Release of IL-6 in NCI-H929 Cytotoxicity Assay

[0815] The results showed that the GPRC5D / CD3 bispecific antibody disclosed herein released lower levels of IL6 and IFNγ than JNJ-64407564, with IL6, in particular, being almost undetectable, suggesting that the GPRC5D / CD3 bispecific antibody disclosed herein has a better safety profile.

[0816] In vivo biological evaluation

[0817] Test Example 6. Efficacy of GPRC5D / CD3 bispecific antibody in NCIH929 subcutaneous transplant tumor model

[0818] The present disclosure uses a human myeloma NCI-H929 cell human PBMC NOG mouse xenograft tumor model to evaluate the anti-tumor activity of the GPRC5D / CD3 bispecific antibody.

[0819] NOG mice, female, 8-10 weeks old, were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd.

[0820] The human multiple myeloma cell line NCI-H929 was purchased from Shanghai Mingjin Biotechnology Co., Ltd.

[0821] NCI-H929 cells were added to RPMI-1640 medium containing 10% FBS and 0.05 mM 2-mercaptoethanol and cultured in a humidified incubator at 37°C with 5% CO2. NCI-H929 cells in the logarithmic growth phase were collected and resuspended in RPMI-1640 medium containing 50% Matrigel to adjust the cell density to 2 × 10 7 Under sterile conditions, 0.1 mL of cell suspension was inoculated subcutaneously on the right side of the mouse back at a concentration of 2 × 10 6 / 0.1mL / mouse. One day after tumor cell inoculation, hPBMCs frozen in liquid nitrogen were revived and cultured in PRMI-1640 medium containing 10% HIFBS (FBS, inactivated at 56°C for 30 minutes). The cells were incubated in a 37°C incubator with 5% CO2 for 6 hours. After incubation, hPBMCs were collected and resuspended in PBS buffer to adjust the cell concentration to 2.5×10 7 Under sterile conditions, 0.2 mL of cell suspension was injected intraperitoneally into mice at an injection concentration of 5 × 10 6 / 0.2mL / mouse. When the average tumor volume reaches 100mm 3Around 6:00 p.m., animals were randomly divided into groups based on tumor volume, ensuring that the difference in tumor volume between groups was less than 10% of the mean. Grouping was designated Day 0, and dosing began according to animal body weight. Immediately after grouping, dosing was performed intraperitoneally once weekly for two consecutive doses (IP, qW x 2), and tumor measurements were recorded. Tumor inhibition rate (%) = 1 - T / C (%). T / C (%) = (T - T0) / (C - C0) x 100%.

[0822] Tumor volume (V) = 1 / 2 × a × b 2 , where a and b represent length and width respectively.

[0823] T and C are the tumor volumes of the treatment group and the control group at the end of the experiment; T0 and C0 are the tumor volumes at the beginning of the experiment.

[0824] Specific results are shown in Tables 30-1, 30-2, 30-3 and Figure 2, where the tumor inhibition rates calculated in the tables are the tumor inhibition rates on the last day.

[0825] Table 30-1. Efficacy of Antibody F2-1 in NCIH929 Subcutaneous Xenograft Tumor Model

[0826] Table 30-2. Pharmacological efficacy of antibodies F4-8, F4-6, F4-7, and F2-4 in the NCIH929 subcutaneous transplant tumor model

[0827] Table 30-3. Efficacy of antibodies F4-0G4S-1 and F2-0G4S-1 in the NCIH929 subcutaneous transplant tumor model

[0828] Experimental results demonstrated that the disclosed GPRC5D / CD3 bispecific antibodies F2-1, F2-4, F4-6, F4-7, F4-8, F2-0G4S-1, and F4-0G4S-1 demonstrated greater in vivo tumor growth inhibition activity than JNJ-64407564 at the indicated dosages. No drug-related animal deaths or other significant drug-related side effects were observed during the experiments.

[0829] Although the above invention has been described in detail with the aid of the accompanying drawings and examples for clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the disclosure. The disclosures of all patent and scientific literature cited herein are expressly incorporated by reference in their entirety.

Claims

1. An antigen binding molecule that specifically binds to GPRC5D and CD3, comprising at least one antigen binding module that specifically binds to GPRC5D and at least one antigen binding module that specifically binds to CD3, wherein the antigen binding module that specifically binds to GPRC5D comprises a heavy chain variable region GPRC5D-VH and a light chain variable region GPRC5D-VL, and the antigen binding module that specifically binds to CD3 comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL; in: (i) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 137, 18, 135, 136 or 138, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or (ii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, 10 or 133, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, 12, 129, 131 or 132, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or (iii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 21, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 140, 22 or 139, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 23, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 25, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 26; or (iv) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 27, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 29, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 144, 30, 141, 142 or 143, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 32; Preferably, (i) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 137, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or (ii) the GPRC5D-VH comprises: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprises: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO:

14.

2. The antigen binding molecule according to claim 1, wherein the antigen binding moiety that specifically binds to GPRC5D comprises: (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, 3, 42 or 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49, 4, 45, 46, 47, 48 or 50; or (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, 1, 33 or 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39, 2, 36, 37, 38, 40 or 41; or (iii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, 5, 51, 52, 53 or 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56, 6 or 57; or (iv) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 67, 7, 58, 59, 60, 61, 62, 63, 64, 65, 66 or 68, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75, 8, 69, 70, 71, 72, 73 or 74; Preferably, (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 46; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 50; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 46; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 50; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 3, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 4; or (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 36; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 38; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 36; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 38; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 1, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 2; or (iii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 57; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 57; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 5, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 6; or (iv) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 67, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 61, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 62, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 64, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 65, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 7, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 8; or More preferably, (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO:35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO:

39.

3. The antigen-binding molecule according to claim 1 or 2, in: The antigen binding module that specifically binds to CD3 comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL, wherein CD3-HCDR1, CD3-HCDR2 and CD3-HCDR3 in the CD3-VH respectively comprise the amino acid sequences of CD3-HCDR1, CD3-HCDR2 and CD3-HCDR3 in SEQ ID NO: 82; and CD3-LCDR1, CD3-LCDR2 and CD3-LCDR3 in the CD3-VL respectively comprise the amino acid sequences of CD3-LCDR1, CD3-LCDR2 and CD3-LCDR3 in SEQ ID NO: 83; Preferably, The CD3-VH has: a CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 76, a CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 78; and the CD3-VL has: a CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 81; More preferably, The CD3-VH comprises the amino acid sequence of SEQ ID NO:82, and the CD3-VL comprises the amino acid sequence of SEQ ID NO:

83.

4. The antigen-binding molecule according to any one of claims 1 to 3, wherein the antigen-binding molecule further comprises an Fc region, the Fc region is preferably an IgG Fc region, and more preferably an IgG 1 Fc region; more preferably, the Fc region comprises one or more amino acid substitutions capable of reducing the binding of the Fc region to an Fcγ receptor; Most preferably, the Fc region is human IgG 1 Fc region, and the amino acids at positions 234 and 235 are A, and the numbering is according to the EU index.

5. The antigen-binding molecule according to claim 4, wherein the Fc region comprises a first subunit Fc1 and a second subunit Fc2 that can associate with each other, and the Fc1 and Fc2 each independently have one or more amino acid substitutions that reduce homodimerization of the Fc region; Preferably, the Fc1 has a protrusion structure according to the pestle-and-mortar technique, and the Fc2 has a hole structure according to the pestle-and-mortar technique, or the Fc1 has a hole structure according to the pestle-and-mortar technique, and the Fc2 has a protrusion structure according to the pestle-and-mortar technique; More preferably, the amino acid at position 366 of Fc1 is W; and the amino acid at position 366 of Fc2 is S, the amino acid at position 368 is A, and the amino acid at position 407 is V, numbering according to the EU index.

6. An antigen binding molecule according to any one of claims 1 to 5, wherein the antigen binding moiety that specifically binds to GPRC5D is Fab; the antigen binding moiety that specifically binds to CD3 is a replaced Fab, or the antigen binding moiety that specifically binds to GPRC5D is a replaced Fab, and the antigen binding moiety that specifically binds to CD3 is Fab; the replaced Fab is a Fab in which the original CH1 and CL are replaced by the Obscurin chain and the Titin chain, respectively, or the original CH1 and CL of the Fab are replaced by the Titin chain and the Obscurin chain, respectively; Preferably, The Titin chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 145 to SEQ ID NO: 163, and the Obscurin chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 164 to SEQ ID NO: 204; More preferably, The titin chain comprises the amino acid sequence of SEQ ID NO: 163 or 161, and the obscurin chain comprises the amino acid sequence of SEQ ID NO: 198 or 199; Most preferably, The titin chain comprises the amino acid sequence of SEQ ID NO: 163, and the obscurin chain comprises the amino acid sequence of SEQ ID NO: 198; or The titin chain comprises the amino acid sequence of SEQ ID NO:161, and the obscurin chain comprises the amino acid sequence of SEQ ID NO:

199.

7. The antigen binding molecule according to claim 5 or 6, wherein at least one antigen binding moiety that specifically binds to GPRC5D and at least one antigen binding moiety that specifically binds to CD3 are directly connected to the N-terminus of the Fc1 or Fc2 subunit through the C-terminus of the CH1 or Obscurin chain or through a linker, and associate into a heterodimer through a disulfide bond at the N-terminus of the Fc1 and Fc2 subunits.

8. An antigen binding molecule according to any one of claims 1 to 7, wherein the antigen binding molecule comprises a first chain having a structure shown in formula (a), a second chain having a structure shown in formula (b), a third chain having a structure shown in formula (c), and a fourth chain having a structure shown in formula (d), (a) [GPRC5D-VH]-[CH1]-[Fc1], (b) [GPRC5D-VL]-CL, (c) [CD3-VH]-[Obscurin chain]-[Fc2], (d) [CD3-VL]-[Titin chain], The structures shown in formulas (a), (b), (c) and (d) are arranged from the N-terminus to the C-terminus; Preferably, The antigen binding molecule comprises: a first chain comprising an amino acid sequence of SEQ ID NO: 118, A second chain comprising the amino acid sequence of SEQ ID NO:102, a third chain comprising the amino acid sequence of SEQ ID NO:86, and a fourth chain comprising the amino acid sequence of SEQ ID NO:

87.

9. The antigen-binding molecule according to claim 7, in: The antigen binding molecule comprises a first chain having a structure shown in formula (e), a second chain having a structure shown in formula (d), a third chain having a structure shown in formula (f), and a fourth chain having a structure shown in formula (b), (e)[CD3-VH]-[Obscurin chain]-[Fc1], (d) [CD3-VL]-[Titin chain], (f) [GPRC5D-VH]-[CH1]-[Fc2], (b) [GPRC5D-VL]-CL, The structures shown in formula (e), (d), (f) and (b) are arranged from the N-terminus to the C-terminus; Preferably, The antigen binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 89, a second chain comprising the amino acid sequence of SEQ ID NO: 87, a third chain comprising the amino acid sequence of SEQ ID NO: 121, and a fourth chain comprising the amino acid sequence of SEQ ID NO:

106.

10. The antigen-binding molecule according to claim 7, in: The antigen binding molecule comprises a first chain having a structure as shown in formula (a), a second chain having a structure as shown in formula (b), a third chain having a structure as shown in formula (g), and a fourth chain having a structure as shown in formula (h), (a) [GPRC5D-VH]-[CH1]-[Fc1], (b) [GPRC5D-VL]-CL, (g) [CD3-VH]-Linker 1-[Obscurin chain]-[Fc2], (h) [CD3-VL]-Linker 2-[Titin chain], The structures represented by formula (a), (b), (g) and (h) are arranged from the N-terminus to the C-terminus, and the linker 1 and linker 2 are the same or different peptide linkers; Preferably, The antigen-binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 118, a second chain comprising the amino acid sequence of SEQ ID NO: 102, a third chain comprising the amino acid sequence of SEQ ID NO: 84, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 85; or The antigen binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 120, a second chain comprising the amino acid sequence of SEQ ID NO: 106, a third chain comprising the amino acid sequence of SEQ ID NO: 84, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 85; or The antigen binding molecule comprises: a first chain comprising an amino acid sequence of SEQ ID NO: 122, a second chain comprising an amino acid sequence of SEQ ID NO: 110, a an amino acid sequence of SEQ ID NO: 85; or The antigen binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 124, a second chain comprising the amino acid sequence of SEQ ID NO: 117, a third chain comprising the amino acid sequence of SEQ ID NO: 84, and a fourth chain comprising the amino acid sequence of SEQ ID NO:

85.

11. The antigen-binding molecule according to claim 7, in: The antigen-binding molecule comprises a first chain having a structure as shown in formula (i), a second chain having a structure as shown in formula (j), a third chain having a structure as shown in formula (f), and a fourth chain having a structure as shown in formula (b), (i) [CD3-VH]-Linker 3-[Obscurin chain]-[Fc1], (j) [CD3-VL]-Linker 4-[Titin chain], (f) [GPRC5D-VH]-[CH1]-[Fc2], (b) [GPRC5D-VL]-CL, The structures shown in formula (i), (j), (f) and (b) are arranged from the N-terminus to the C-terminus, and the linker 3 and the linker 4 are the same or different peptide linkers; Preferably, The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 116, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 117; or The antigen binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 121, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 106; or The antigen binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 123, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 110; or The antigen-binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 119, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 102; or The antigen binding molecule has: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 115, and a fourth chain comprising the amino acid sequence of SEQ ID NO: 117; or The antigen binding molecule comprises: a first chain comprising the amino acid sequence of SEQ ID NO: 88, a second chain comprising the amino acid sequence of SEQ ID NO: 85, a third chain comprising the amino acid sequence of SEQ ID NO: 227, and a fourth chain comprising the amino acid sequence of SEQ ID NO:

223.

12. The antigen binding molecule according to claim 5, wherein the antigen binding molecule comprises two antigen binding modules that specifically bind to GPRC5D and two antigen binding modules that specifically bind to CD3, wherein the antigen binding module that specifically binds to GPRC5D is Fab; and the antigen binding module that specifically binds to CD3 is scFv; Preferably, The antigen binding molecule comprises two first chains having a structure represented by formula (k) and two second chains having a structure represented by formula (b), (k) [GPRC5D-VH]-[CH1]-[CD3-VH]-Linker 5-[CD3-VL]-Linker 6-[a subunit of Fc], (b) [GPRC5D-VL]-CL, The structures shown in formula (k) and (b) are arranged from the N-terminus to the C-terminus, and the linker 5 and the linker 6 are the same or different peptide linkers; More preferably, The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 98 and two second chains comprising the amino acid sequence of SEQ ID NO: 100; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 98 and two second chains comprising the amino acid sequence of SEQ ID NO: 101; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 98 and two second chains comprising the amino acid sequence of SEQ ID NO: 102; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 99 and two second chains comprising the amino acid sequence of SEQ ID NO: 100; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 99 and two second chains comprising the amino acid sequence of SEQ ID NO: 101; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 99 and two second chains comprising the amino acid sequence of SEQ ID NO: 102; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 103 and two second chains comprising the amino acid sequence of SEQ ID NO: 105; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 103 and two second chains comprising the amino acid sequence of SEQ ID NO: 106; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 103 and two second chains comprising the amino acid sequence of SEQ ID NO: 107; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 104 and two second chains comprising the amino acid sequence of SEQ ID NO: 105; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 104 and two second chains comprising the amino acid sequence of SEQ ID NO: 106; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 104 and two second chains comprising the amino acid sequence of SEQ ID NO: 107; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 108 and two second chains comprising the amino acid sequence of SEQ ID NO: 110; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 109 and two second chains comprising the amino acid sequence of SEQ ID NO: 110; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 108 and two second chains comprising the amino acid sequence of SEQ ID NO: 111; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 109 and two second chains comprising the amino acid sequence of SEQ ID NO: 111; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 224 and two second chains comprising the amino acid sequence of SEQ ID NO: 217; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 225 and two second chains comprising the amino acid sequence of SEQ ID NO: 219; or The antigen binding molecule has: two first chains comprising the amino acid sequence of SEQ ID NO: 226 and two second chains comprising the amino acid sequence of SEQ ID NO:

221.

13. An isolated antibody capable of specifically binding to GPRC5D, the antibody comprising a heavy chain variable region GPRC5D-VH and a light chain variable region GPRC5D-VL, in: (i) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 137, 18, 135, 136 or 138, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or (ii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, 10 or 133, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, 12, 129, 131 or 132, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 14; or (iii) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 21, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 140, 22 or 139, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 23, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 25, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 26; or (iv) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 27, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 29, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 144, 30, 141, 142 or 143, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 32; Preferably, (i) the GPRC5D-VH has: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 15, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 17, and the GPRC5D-VL has: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 137, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO: 20; or (ii) the GPRC5D-VH comprises: a GPRC5D-HCDR1 comprising the amino acid sequence of SEQ ID NO: 9, a GPRC5D-HCDR2 comprising the amino acid sequence of SEQ ID NO: 134, and a GPRC5D-HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and the GPRC5D-VL comprises: a GPRC5D-LCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a GPRC5D-LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a GPRC5D-LCDR3 comprising the amino acid sequence of SEQ ID NO:

14.

14. The isolated antibody according to claim 13, in: (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, 3, 42 or 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49, 4, 45, 46, 47, 48 or 50; or (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, 1, 33 or 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39, 2, 36, 37, 38, 40 or 41; or (iii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, 5, 51, 52, 53 or 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56, 6 or 57; or (iv) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 67, 7, 58, 59, 60, 61, 62, 63, 64, 65, 66 or 68, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75, 8, 69, 70, 71, 72, 73 or 74; Preferably, (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 46, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 43, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 50, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 46, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 50; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 3, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 4; or (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 36, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 38, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 34, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 39, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 36, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 38, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 1, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 2; or (iii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 56, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 54, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 57, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 55, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 57; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 5, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 6; or (iv) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 67, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 61, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 62, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 64, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75, or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 65, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 75; or The GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 7, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 8; or More preferably, (i) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO: 44, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO: 49; or (ii) the GPRC5D-VH comprises the amino acid sequence of SEQ ID NO:35, and the GPRC5D-VL comprises the amino acid sequence of SEQ ID NO:

39.

15. The isolated antibody according to claim 13 or 14, wherein the antibody is a bispecific antibody; Preferably, the bispecific antibody specifically binds to GPRC5D and CD3.

16. The antigen binding molecule according to any one of claims 1 to 12 or the isolated antibody according to any one of claims 13 to 15, wherein the antigen binding molecule or the isolated antibody does not bind to E2 peptide, E3 peptide and E4 peptide, wherein the E2 peptide comprises the amino acid sequence of SEQ ID NO: 206, the E3 peptide comprises the amino acid sequence of SEQ ID NO: 207, and the E4 peptide comprises the amino acid sequence of SEQ ID NO: 208; Preferably, the antigen binding molecule or isolated antibody binds to the amino terminal region of human GPRC5D, wherein the amino terminal region of human GPRC5D comprises the amino acid sequence of SEQ ID NO:

205.

17. A pharmaceutical composition comprising: A therapeutically effective amount of the antigen binding molecule of any one of claims 1 to 12 or the isolated antibody of any one of claims 13 to 15, and one or more pharmaceutically acceptable carriers, diluents, buffers or excipients; Preferably, the pharmaceutical composition further comprises at least one second therapeutic agent.

18. An isolated nucleic acid encoding the antigen binding molecule of any one of claims 1 to 12 or the isolated antibody of any one of claims 13 to 15.

19. A host cell comprising the nucleic acid of claim 18.

20. A method for treating a disease, the method comprising the step of administering to a subject the antigen binding molecule of any one of claims 1 to 12, the isolated antibody of any one of claims 13 to 15, or the pharmaceutical composition of claim 17; Preferably, the disease is a tumor, cancer or autoimmune disease; More preferably, the disease is multiple myeloma, relapsed / refractory multiple myeloma, smoldering multiple myeloma, monoclonal gammopathy, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, Burkitt's lymphoma, follicular lymphoma, mantle cell lymphoma, Waldenstrom's macroglobulinemia, plasma cell leukemia, light chain amyloidosis, precursor B-cell lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome symptoms, chronic lymphocytic leukemia, B-cell malignancies, chronic myeloid leukemia, hairy cell leukemia, blastic plasmacytoid dendritic cell neoplasm, Hodgkin lymphoma, non-Hodgkin lymphoma, marginal zone B-cell lymphoma, mucosa-associated lymphoid tissue lymphoma, plasma cell leukemia, anaplastic large cell lymphoma, ovarian cancer, lung cancer, stomach cancer, prostate cancer, kidney cancer, liver cancer, colorectal cancer, esophageal cancer, bladder cancer, cervical cancer, or melanoma.